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Abstract 
 
Introduction:  Mutations in cardiac myosin binding protein-C (MYBPC3), the 
most common genetic cause of hypertrophic cardiomyopathy (HCM), have been reported 
to cause a comparatively benign and late-onset form of the disease with incomplete 
penetrance. Based upon selected families with small numbers of mutations, these early 
reports may be misleading however. This study aimed to redefine the clinical 
characteristics of HCM related to MYBPC3 by evaluating a large cohort of unselected 
patients and their families, in whom an MYBPC3 mutation had been identified. 
Methods:  Index cases and their families underwent history, physical examination, 
electrocardiogram (ECG), transthoracic echocardiography, ambulatory ECG monitoring, 
metabolic exercise testing and mutation analysis. Long-term follow up data was collected 
where available. 
Results:   44 MYBPC3 mutations were identified in 59 index cases. 26 of 59 (44%) 
were missense with 11 (19%) insertions/deletions, 11 (19%) intronic, and 5 (8%) 
nonsense mutations. A further 6 (10%) had complex genetic status with two different 
sequence variations identified. Nine families shared the R502W missense mutation and 
haplotype analysis confirmed a common founder, the first to be described in a UK cohort. 
A further 111 mutation carriers were identified, of which 39 were clinically affected - 
disease penetrance was therefore incomplete (58%) and related to age and gender but not 
mutation type. Mean age at diagnosis was 40.1 +/- 15.9 years with a wide range (5-76); 
91.8% of affected mutation carriers were diagnosed over the age of 20 years. Most had 
asymmetric septal hypertrophy (86.4%) and mean maximal wall thickness was 20 +/-   5 
5.8mm. Families sharing identical mutations showed significant variability in disease 
penetrance, age at diagnosis and risk of sudden death, suggesting that modifying factors 
play a significant role in disease development. No clinically useful markers of early 
disease expression were apparent from tissue Doppler studies in unaffected genotyped 
relatives. During long term follow up (mean 7.9 +/- 4.5 years) 1 individual developed 
hypertrophy as an adult, 5 individuals died (3 suddenly) and overall survival was 94%.  
 
Discussion:  The broad spectrum of mutations, disease severity and natural 
history of disease suggests that earlier reports of late-onset, benign disease related to 
MYBPC3 mutations were premature. In this study disease expression is broadly similar 
to non-genotyped HCM cohorts with disease severity ranging from mild to severe, risk of 
sudden death ranging from low to high and clinical disease being diagnosed in all 
decades of life. Such variance is not adequately explained by the sarcomeric protein gene 
or specific mutation per se and other genetic and environmental factors influence disease 
penetrance, severity and prognosis. The next generation of genotype-phenotype studies 
require a shift in focus from single gene analysis to include other genetic and 
environmental variables and an international collaborative database is recommended.  6 
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INTRODUCTION  15 
 
Pre-amble 
 
 
Since the initial description of „asymmetric hypertrophy of the heart in young adults‟ by 
Donald Teare in 1958 [Teare 1958], the condition now known as Hypertrophic 
Cardiomyopathy (HCM) has captured the imagination of clinicians, pathologists, 
geneticists and patients alike. The first descriptions linked the finding of severe cardiac 
hypertrophy with sudden cardiac death, and demonstrated the familial nature of this 
condition [Goodwin 1960][Pare 1961][Braunwald 1964]. Our understanding of HCM 
however has developed at great pace with the advent of molecular genetics and advanced 
cardiac imaging, but we are beginning to understand that the complexities of this 
condition are great and numerous. Over the last 15 years or so, genetic mutation analysis 
has been particularly helpful giving us insight into the molecular pathogenesis of HCM – 
„a disease of the sarcomere‟ and providing an opportunity for pre-clinical diagnosis in 
some families. The relationship between genotype and phenotype is not straightforward 
however and has received considerable attention by investigators striving to explain the 
clinical heterogeneity of this condition. The focus of this thesis is to provide further 
insights into the relationship between genotype and phenotype in patients with mutations 
in the gene encoding cardiac myosin binding protein-C (MYBPC3).   16 
Overview of Hypertrophic Cardiomyopathy 
 
Definition and Diagnosis 
Hypertrophic cardiomyopathy (HCM) is defined clinically by ventricular hypertrophy in 
the absence of an identifiable cause [Maron 2003a][Maron 2006]. Most investigators 
would consider this to be a maximal wall thickness ≥13 mm, or more than 2 standard 
deviations from the mean corrected for age, size and gender [Maron 2003a] [Elliott 
2004]. This definition, while useful clinically, lacks precision and sensitivity as certain 
forms of HCM are associated with minimal hypertrophy [Thierfelder 1994], and it 
excludes family members who have inherited the family mutation with signs of early 
disease expression, although diagnostic criteria for family members have been proposed 
[McKenna 1997]. The diagnosis is traditionally best made with 2-dimensional 
transthoracic echocardiography (TTE) but recommendations for including 
electrocardiographic (ECG) abnormalities in the diagnostic criteria exist [McKenna 
1997]. 
 
Epidemiology 
The population prevalence of HCM in adults is estimated to be approximately 1 in 500 
(0.2%) [Maron 1995] based on echocardiographic screening in a young adult population, 
but this may be an underestimate if a broader definition of HCM is used. 
   17 
Pathology 
HCM is characterized macroscopically by left ventricular hypertrophy. The pattern and 
degree of ventricular hypertrophy is highly variable. It is usually predominant in the left 
ventricle (but can be biventricular) and usually affects the interventricular septum (the 
„classical‟ asymmetric septal hypertrophy). It may also be concentric however, or 
eccentric involving any other ventricular wall including the apex [Maron 1983]. 
Hypertrophy may be associated with anterior displacement of the papillary muscles and 
mitral valve abnormalities leading to systolic anterior motion of the leaflets. If this 
anterior motion is complete and prolonged, obstruction to systolic ejection may occur in 
the left ventricular outflow tract with a resulting pressure gradient between the left 
ventricular cavity and the aorta. This dynamic process called left ventricular outflow tract 
obstruction (LVOTO) is present in perhaps 25% of individuals at rest and up to 70% of 
individuals on exertion or altered loading conditions, and is a major cause of morbidity in 
the HCM population [Maron 2006]. Other important abnormalities include diastolic 
dysfunction, left atrial enlargement and mitral regurgitation. 
On a histological level the classical pathological features of HCM are those of interstitial 
fibrosis with myocyte hypertrophy and disarray [Ferrans 1972][Factor 1991][Shirani 
2000][Varnava 2001]. Disarray is patchy and consists of obliquely aligned and irregular 
hypertrophied myocytes. There is nuclear enlargement, polychromasia and pleomorphism 
[Hughes 2004] and an increase in interstitial fibrosis and with altered collagen fibre 
morphology [Shirani 2000]. Intramural arteriolar hypertrophy and dysplasia is seen and 
may account for reduced coronary flow and small vessel ischaemia [Maron 1986a] 
[Varnava 2000].    18 
Aetiology and Pathogenesis 
Genetic linkage studies and candidate-gene screening techniques have identified that 
mutations in sarcomeric protein genes account for approximately 60% of cases of HCM 
[see Table 1 for references]. Other molecular abnormalities include metabolic disorders 
such as Anderson-Fabry disease, AMP-kinase disease and glycogen storage disorders. 
Table 1   Spectrum of pathogenic genes identified in HCM 
  Abbreviation  Reference  
Sarcomeric Protein disease     
Cardiac myosin binding protein C  MYBPC3  Bonne 1995 
Watkins 1995a 
Beta-myosin heavy chain  MYH7  Geisterfer-Lowrance 1990 
Cardiac troponin T  TNNT2  Thierfelder 1994 
Cardiac troponin I  TNNI3  Watkins 1993 
Kimura 1997 
Alpha-tropomyosin  TPM1  Watkins 1995b 
Essential myosin light chain  MYL3  Poetter 1996 
Regulatory myosin light chain  MYL2  Poetter 1996 
Alpha cardiac actin  ACTC  Mogensen 1999 
Alpha-myosin heavy chain  MYH6  Carniel 2005 
Niimura  2002 
Titin  TTN  Satoh 1999 
Cardiac troponin C  TNNC1  Hoffman 2001 
Sarcomere Associated Protein Genes     
Muscle LIM protein  CSRP3  Geier 2003 
Myosin light chain kinase 2  MYLK2  Davis 2001 
LIM binding domain 3  LDB3  Theis 2006 
Telethonin  TCAP  Hayashi 2004 
Vinculin/metavinculin  VCL  Vasile 2006a 
Vasile 2006b 
α-Actinin 2  ACTN2  Theis 2006 
Phospholamban  PLN  Haghighi 2006 
Myozenin 2  MYOZ2  Osio 2007 
Junctophillin 2  JPH2  Lansdtrom 2007 
Metabolic disorders     
AMP-activated protein kinase  PRKAG2  AMP Kinase disease 
Blair 2001 
α-Galactosidase A  GLA  Anderson Fabry disease 
Sachdev 2002 
Acid α-1,4-glucosidase  GAA  Pompe disease 
Amato 2000 
Amylo-1, 6-glucosidase  AGL  Forbe‟s disease 
Amato 2000 
Lysosome-associated membrane protein 2  LAMP2  Danon disease 
Amato  2000 
Mitochondrial disorders  Various genes  MELAS, LOHN, MERRF 
DiMauro 2003 
Syndromic disorders     
Tyrosine phosphatase SHP-2  PTPN11  LEOPARD syndrome, Noonan 
syndrome 
Tartaglia 2002 
Sarkozy  2003 
Frataxin  FRDA  Friedrich‟s ataxia 
Palau 2001 
     
   19 
The link between genetic mutation and the clinical phenotype of HCM is poorly 
understood. A number of different mechanisms may play a part including „poison 
polypeptide‟ or „dominant negative‟ effect where the mutated allele affects function of 
the wild-type allele, or haploinsufficiency where the wild-type allele is unable to produce 
sufficient normal functional protein. This may be an important mechanism in some 
families with MYBPC3 related disease where the post-translational protein product is so 
small that effective incorporation into the sarcomere would be impossible [Andersen 
2004]. 
The mechanism by which such molecular abnormalities cause the clinical features of 
HCM is varied and poorly understood. It is thought that the hallmark finding of 
hypertrophy is a secondary phenomenon to underlying abnormalities in myocyte function 
[Redwood 1999] and abnormal myocardial bioenergentics may play a pivotal role 
[Watkins 2003].  
 
Clinical Disease Expression 
The earliest descriptions of the disease necessarily focused on cases with severe 
hypertrophy and an obvious clinical phenotype [Teare 1958][Goodwin 1960][Pare 1961]. 
Sudden cardiac death was prominent leading health professionals and the lay public alike 
to fear the disease [Braunwald 1964]. However these early descriptions exaggerated the 
severity of disease and gloomy prognosis, as severe clinically obvious cases were 
overrepresented in these series. In fact the majority of patients in the community with 
HCM remain undiagnosed and are without symptoms with near normal life-expectancies.    20 
There exists therefore a remarkably heterogeneous spectrum of disease severity. 
Presentations vary from neonatal heart failure [Lekanne Deprez 2006], sudden cardiac 
death in young adults, symptomatic left ventricular outflow tract obstruction, an 
incidental ECG abnormality, and asymptomatic elderly relatives diagnosed during family 
screening [Maron 2002]. 
While many patients are asymptomatic, the spectrum of clinical symptoms when present 
includes exertional chest pain, breathlessness, palpitations, syncope and pre-syncope. 
There are a number of different pathophysiological mechanisms responsible for causing 
symptoms which may co-exist in the same patient. Hypertrophy (the hallmark of clinical 
diagnosis) results in abnormal diastolic ventricular function and a consequent increase in 
left ventricular end-diastolic pressure. The resultant increase in left atrial pressure 
contributes to left atrial dilatation and predisposes the individual to atrial 
tachyarrhythmias. Arteriolar smooth muscle hyperplasia may induce ischaemia with 
scarring and fibrosis predisposing to ventricular arrhythmias [Varnava 2000].  
Left ventricular outflow tract obstruction (LVOTO) occurs in 25% of individuals at rest 
(and up to 70% on exercise) [Maron 2006] and is an important cause of both symptoms 
and mortality [Elliott 2006a]. LVOTO occurs in the presence of systolic anterior motion 
of the mitral valve and is highly labile. The pressure gradient in the LVOT is susceptible 
to changes in pre-load and after-load and may be inducible with manoeuvres such as 
Valsalva or exercise. Modifying LVOTO has been a focus of therapeutic strategies for 
many years. 
   21 
Early reports described a high incidence of sudden death in selected cohorts of patients 
with HCM [Braunwald 1964]. Sudden death remains an important, but relatively 
uncommon complication of this disease with an annual mortality rate of approximately 
1% in unselected cohorts [Maron 2000a]. HCM however remains the leading cause of 
sudden cardiac death in athletes [Maron 1996]. It is likely that a combination of a 
predisposing arrhythmic substrate (such as severe hypertrophy, fibrosis and disarray) and 
subsequent triggers (such as exercise or ischaemia) are responsible for inducing 
ventricular arrhythmias [Frenneaux 2000] which is frequently the terminal event in 
individuals dying suddenly with HCM [Maron 2000b]. 
Accurately identifying individuals „at risk‟ has received considerable interest from 
investigators and algorithms exist to risk stratify patients and guide prophylactic therapies 
[Elliott 2000][Maron 2002a][Frenneaux 2004]. Such algorithms are imperfect however 
and such decisions should be individualized as much as possible. Current consensus 
guidelines [Maron 2003a] base risk stratification for sudden cardiac death risk upon 5 
established risk factors: a family history of sudden premature cardiac death, maximal 
wall thickness ≥ 30mm, an abnormal blood pressure response on exercise, unexplained 
syncope and non-sustained VT on Holter monitoring [Elliott 2000]. The relative risk of 
sudden death is related to the number of risk factors present in an individual. It should be 
noted that the significance of a risk factor is age dependent - the presence of non-
sustained VT in a child is significantly more predictive than in a 60 year old for example. 
Risk factors for sudden cardiac death and stroke are listed in Tables 2 and 3. 
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Table 2   Predictors and risk factors for Sudden Cardiac Death in HCM   
Risk Factor  Definitions   
Major risk factors*     
Previous cardiac arrest  Previous documented cardiac arrest 
with successful resuscitation 
 
Family history of sudden premature cardiac death     
Severe hypertrophy  Maximal wall thickness ≥ 30mm   
Abnormal blood pressure response in patients < 40 years of age  Failure to rise > 25mmHg from 
baseline to end of exercise OR a 
fall > 15mmHg from peak exercise 
to end exercise 
 
Unexplained syncope  Syncope in absence of identifiable 
cause (e.g. LVOT obstruction) 
 
Non-sustained VT   3 or more beats of VT (rate > 120 
bpm) 
 
     
Other proposed risk factors     
Left ventricular outflow tract obstruction     
Myocardial ischaemia     
Late gadolinium enhancement on magnetic resonance imaging     
Mutation specific risk     
* Elliott 2000     
 
Stroke is also an important complication in HCM with an annual incidence of 
approximately 0.8% [Maron 2002a] and is a leading cause of death (with sudden death 
and heart failure) in the HCM population. Risk factors for stroke include female gender, 
increasing age, left atrial enlargement and congestive heart failure but the major risk 
factor is atrial fibrillation with 88% of all strokes occurring in individuals with a history 
of atrial fibrillation [Maron 2002a]. 
Table 3 Risk factors for Stroke in HCM* 
 
Atrial fibrillation  
Left atrial enlargement 
Congestive symptoms 
Increasing age 
* Maron 2002a 
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Table 4 Clinical symptoms, signs and complications in HCM 
 
Symptoms 
Chest pain 
Breathlessness 
Syncope / Pre-syncope 
Fatigue 
Palpitations 
Fluid retention 
 
Clinical Signs 
Sustained apical impulse 
Rapid upstroke pulse 
Ejection systolic murmur related to outflow tract obstruction 
Pansystolic murmur related to mitral regurgitation 
 
Complications 
Atrial arrhythmias 
Ventricular arrhythmias and sudden death 
Systemic thromboembolism including stroke 
Infective endocarditis 
Diastolic dysfunction and heart failure 
Left ventricular systolic dysfunction and heart failure 
 
 
 
Management 
The majority of individuals with HCM are asymptomatic. In these individuals 
management is limited to lifestyle advice, education, genetic counseling and often 
reassurance. In the remainder a number of strategies exist to modify symptoms, however 
few randomized trial data exist to guide management decisions.  
A major cause of symptoms in HCM is LVOTO and gradient reduction therapy has 
received considerable interest as a therapeutic measure in symptomatic patients. The 
mainstay of therapy are agents aimed at reducing inotropic work: beta-blockers, calcium 
channel blockers such as verapamil, and class 1 agents such as disopyramide [Sherrid 
2005] have been used effectively in reducing LVOTO [Maron 2003a]. While such drugs 
may be useful for symptomatic relief it must be borne in mind that no data exist to 
support their use in asymptomatic patients, despite the theoretical potential benefits in 
reducing LVOT gradient. In patients in whom medical therapy has been unsuccessful a   24 
number of percutaneous and surgical strategies exist aimed at reducing LVOT gradient. 
Alcohol septal ablation, in which a portion of the interventricular septum is „ablated‟ with 
intracoronary absolute alcohol has been performed for over 13 years and has become a 
well established method of gradient reduction therapy [Sigwart 1995] [Knight 
1997][Faber 2000]. In some centres surgical myomectomy has been performed safely and 
effectively although the requirement for cardiopulmonary bypass carries limitations and 
associated risk [Koch 1980]. Programmed ventricular pacing has also received attention 
as a therapeutic option especially in those unsuitable for more aggressive forms of 
gradient reduction therapy, or in whom a device was indicated for another reason [Gadler 
1999]. While some patients benefit symptomatically, randomized trials have been 
contradictory and the use of pacing is not widespread [Kappenberger 1997][Nishimura 
1997][Kappenberger 1999].  
In individuals without LVOTO therapeutic strategies may be aimed at reducing 
arrhythmic burden with beta-blockers or amiodarone and alleviating heart failure 
symptoms. It is yet unknown whether the natural history of disease can be modified in 
asymptomatic individuals and randomized trials are urgently required in this group of 
patients. 
Prognosis 
Although the common perception amongst lay people and health professionals is that 
HCM is a feared diagnosis, the overall prognosis in unselected cohorts is relatively good. 
In a large cohort of unselected patients followed up for a mean 8.0 +/- 7 years HCM-
related death during follow up occurred in 12% with three modes of death accounting for 
the majority [Maron 2000a] - sudden death, heart failure death and fatal stroke. Mode of   25 
death appears to be age related with sudden death being more prominent in the young and 
heart failure and stroke deaths being more prevalent later in life. Previous studies have 
suggested that an increased risk of sudden death is associated with specific genotypes 
(such as TNNT2 mutations [Watkins 1995b][Moolman 1997]) while others may carry a 
more benign prognosis (such as MYBPC3 mutations [Charron 1998a][Niimura 1998]) 
but whether these initial observations extend to large numbers of unselected individuals 
remains to be seen.  
In published series to date, the overall annual incidence of major complications is as 
follows: 
  sudden cardiac death - less than 1% [Maron 2000a][Maron 2002b] (although 
some individuals are at a much higher individual risk).  
  stroke – approximately 0.8% [Maron 2002a].  
  infective endocarditis - approximately 0.1% [Spirito 1999].  
  end-stage disease (related to left ventricular systolic dysfunction) - 0.87% 
[Thaman 2005].  
The incidence of sudden death may be modified however with implantable cardioverter-
defibrillator implantation [Maron 2008] which can successfully cardiovert ventricular 
tachycardia or fibrillation and abort sudden death [Maron 2007]. 
 
Genotype-Phenotype Correlations 
Hypertrophic cardiomyopathy is a diverse heart muscle disease: 
  Mutations in one of many different genes encoding both sarcomeric and non-
sarcomeric proteins cause the disease   26 
  The spectrum of disease is broad – it can present at any stage in life with a wide 
range of symptoms and complications 
Such clinical diversity makes managing patients and families with the condition 
challenging as the clinician has to educate, inform and predict outcome for his patients 
based on knowledge about the disease which often appear conflicting.  
In order to examine determinants of the clinical diversity, early studies focused on 
whether the clinical variation between individuals could be explained by differences in 
the molecular genetic abnormality. A few early studies have led to accepted views on 
differences in patterns of disease expression that are gene-specific. These are summarized 
in Table 5. 
Table 5   Summary of Published Genotype-Phenotype Correlation Studies in HCM 
Gene  Observed phenotype  References 
MYBPC3  Late-onset, low penetrance, benign 
clinical course 
Niimura 1998 
Charron 1998a 
MYH7  Severe hypertrophy with high risk of 
sudden death 
Anan 1994 
TNNT2  Mild hypertrophy, high risk of sudden 
cardiac death 
Moolman 1997 
Watkins 1995b 
TNNI3  Variable 
? restrictive cardiomyopathy 
Mogensen 2004 
Doolan 2005 
Kubo 2007 
TPM1  Variable, sudden death reported  Watkins 1995b 
MYL3  Variable, skeletal myopathy  Poetter 1996 
MYL2  Variable, skeletal myopathy  Poetter 1996 
ACTC  Rare, apical hypertrophy  Mogensen 1999 
MYH6  Rare, ? late onset  Carniel 2005 
Niimura  2002 
TTN  Rare, typical HCM  Satoh 1999 
TNNC1  Rare, Typical  Hoffman 2001  
Others  Rare  See references in Table 1. 
     
 
While these early observations were welcome – purporting to explain to some extent the 
clinical diversity seen in HCM – there are a number of important limitations when 
considering these genotype-phenotype studies: 
  Reports were based upon small numbers of mutations for each gene which may 
not be representative of the overall population   27 
  In some cases the majority of data was obtained from small numbers of families 
which introduces selection bias  
  Most studies are conducted at large tertiary referral centres which include an 
element of referral bias. 
  Although the statistical mean for a given parameter may differ between different 
genes the variation in data may be similar and the differences in the calculated 
mean may not be clinically relevant. 
   28 
Cardiac Myosin Binding Protein C 
 
In most cross-sectional series of individuals with HCM, MYBPC3 mutations are the most 
commonly identified (Van Driest 2005). The mechanisms underlying the pathogenic 
effects of MYBPC3 mutations are complex however and poorly understood. Cardiac 
myosin binding protein C (MyBP-C) is a polypeptide with a molecular weight of 
approximately 135 kDa [Winegard 1999]. It is a thick-filament associated protein which 
is localized to the C zone of the A band of the sarcomere [Robbins 2002] (Figure 1). It 
has 10 globular domains of which 7 are immunoglobulin I-like and 3 are fibronectin-3 
like. MyBP-C binds to myosin via the terminal C10 domain and titin via C9 or C10 
domains.  
   29 
Figure 1 Structure of the Cardiac Sarcomere and MYBPC Protein 
Its role in sarcomeric contraction is poorly defined but is thought to include the assembly, 
maintenance of structural integrity and regulation of contractile activity of the sarcomere 
[Flashman 2004][Oakley 2004]. Interestingly knock-out mice (with no functional MyBP-
C) are viable and assembly of the sarcomere is possible, albeit disordered, suggesting that 
MyBP-C is not absolutely essential for sarcomere formation [Harris 2002]. Cardiac 
hypertrophy and contractile dysfunction still occurred however. 
The gene encoding cardiac myosin binding protein C (MYBPC3) is located on the short 
arm of chromosome 11 (11p11.2) and comprises 35 exons of which two are unusually 
small (3 base pairs each) [Carrier 1997].  Pathogenic mutations have been reported 
throughout the entire length of the protein (for an on-line list of reported mutations see 
http://genetics.med.harvard.edu/~seidman/cg3/muts/MYBPC3_mutations_TOC.html).    30 
In contrast to other sarcomeric protein genes, mutations in MYBPC3 commonly result in 
a truncated protein product suggesting that haploinsufficiency may play an important role 
in disease pathogenesis in some families. Moolman et al. examined protein expression in 
a large family sharing a single base insertion in exon 25 resulting in premature truncation 
and loss of the terminal myosin and titin binding sites [Moolman 2000]. Abnormal 
mutated protein was not demonstrated in human myocardial tissue obtained from surgical 
myectomy suggesting that the mechanism leading to disease development in this instance 
was haploinsufficiency (i.e. absence of normal protein) rather than the „dominant-
negative‟ effect proposed for missense mutations, observed commonly in other 
sarcomeric protein genes. Haploinsufficiency has been proposed by others as an 
important mechanism of disease development, at least in some families, with HCM 
related to MYBPC3 mutations [Rottbauer 1997][Flashman 2004] [Andersen 2004]. 
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The Spectrum of Clinical Disease in Patients with MYBPC3 Mutations 
A Historical Perspective 
In 1990 affected family members of a large French-Canadian family (originally described 
by Pare et al. in 1961 [Pare 1961]) were found to be heterozygous for the R403Q 
mutation in the MYH7 sarcomeric protein gene [Geisterfer-Lowrance 1990]. Subsequent 
studies identified mutations in other sarcomeric protein genes - TNNI3 [Watkins 1993], 
TNNT2 [Thierfelder 1994] and TPM1 [Watkins 1995b]. 
In 1993, Carrier et al. had mapped a different familial HCM locus to chromosome 11 
[Carrier 1993]. Using a large multi-generational family with multiple affected family 
members they were able to map the probable locus using micro satellite markers and 
linkage techniques. Although few clinical data were reported, the authors felt that this 
particular family was not noticeably different to other families with MYH7 mutations 
they had seen, leading them to conclude that mutations at this locus caused „the same 
phenotype as that described previously‟. It is important to understand however, that in 
order to perform linkage studies large families with multiple affected family members are 
required – not necessarily typical of the broader HCM population. Two years later, the 
same group were able to identify a splice acceptor site mutation in the MYBPC3 gene at 
this locus on chromosome 11 in the same family [Bonne 1995]. Interestingly the mutation 
was also present in several clinically unaffected family members raising the possibility of 
incomplete penetrance – a challenging concept for the clinician and geneticist. Previously 
mutations in the MYH7 gene were thought to be highly penetrant [Anan 1994] although 
reports of incomplete penetrance had been made [Fannapazir 1994]. Simultaneously, and 
reported in the same edition of Nature Genetics, Watkins et al. identified a splice donor   32 
mutation and duplication mutation in MYBPC3 in two large multigenerational families 
[Watkins 1995a]. These families also both showed high but incomplete disease 
penetrance.  
In 1997, Carrier et al. characterized the entire sequence for the MYBPC3 gene and 
identified a further 6 mutations from 7 families with familial HCM. Of 43 mutation 
carriers, only 29 were clinically affected confirming previous reports of incomplete 
disease penetrance (in this case 67%).  
As further sarcomeric genes were identified as disease causing in HCM, and further 
individual mutations were identified, the focus of research switched from gene 
identification towards genotype-phenotype correlation studies in an attempt to explain the 
marked diversity in clinical disease expression - a discussion of some of the important 
themes relating to MYBPC3 mutations follows. 
 
Prevalence of MYBPC3 Mutations in Patients with HCM 
A number of studies have systematically screened patients with HCM for mutations in 
genes encoding sarcomeric proteins to estimate the relative frequency of mutations for 
each gene. This is of importance to the clinician or geneticist, especially if phenotypic 
differences exist between each particular genotype. Geographical or ethnic variations 
may exist and it is important that a wide selection of cohorts in different patient 
populations is examined to highlight any important differences.  
Erdmann et al. screened 110 unrelated patients from Germany and Turkey with HCM 
(defined as maximal wall thickness > 15mm) for mutations in MYBPC3 [Erdman 2001].   33 
13 mutations in 15 families were found accounting for approximately 15% of the overall 
HCM population. No other sarcomeric protein genes were screened however.  
Niimura et al. examined the spectrum of mutations in a defined group of elderly patients 
with late-onset HCM (diagnosed over the age of 40) [Niimura 2002]. 31 individuals (18 
female, 13 male) were screened. Mutations were identified in MYBPC3 (5 mutations), 
TNNI3 (2 mutations) and MYH6 (1 mutation). MYBPC3 mutations accounted for only 
16% of the overall population, but 62.5% of those in whom a mutation was identified. 
 
Alders et al. reported a founder mutation 2373insG in MYBPC3 which was identified in 
23% of patients with HCM in the Netherlands [Alders 2003]. Initially they screened 22 
patients for sarcomeric protein gene mutations and found an unexpectedly high 
proportion of unrelated individuals having this mutation. They then examined the DNA 
of a further 237 unrelated Dutch patients with HCM and found a further 50 carriers of the 
2373insG mutation giving an overall prevalence of 23% throughout the whole Dutch 
HCM population. Haplotype analysis confirmed the presence of a founder effect over 25 
generations previously. No clinical data was reported in this study. 
 
Morner et al. examined the spectrum of sarcomeric protein gene mutations in a Swedish 
population of 46 patients with familial or sporadic HCM [Morner 2003]. 7 MYBPC3 
mutations were identified in 10 families with double heterozygosity occurring in one 
family with a MYH7 mutation. 5 missense, 1 nonsense and 1 frameshift mutation were 
identified. The overall prevalence of MYBPC3 in this cohort was 21.7%. This study   34 
demonstrated the geographical and phylogenetic variation in different patient populations 
as MYBPC3 was the most common disease gene in this Swedish population. 
 
Richard et al. screened 197 unrelated index cases in a French population for sarcomeric 
protein gene mutations. Disease causing mutations were identified in 124 index cases 
(64%) [Richard 1999]. MYBPC3 and MYH7 mutations accounted for 42% and 40% 
respectively of those in whom a mutation was identified but MYBPC3 mutations 
accounted for 26.4% of the overall population. Of the 39 MYBPC3 mutations, 26 
(66.7%) were frameshift or nonsense mutations including splice site mutations. The 
remainder (33.3%) were missense mutations. An important additional finding in this 
study was a high prevalence of families with complex genetic status (either compound or 
double heterozygotes or homozygotes) which occurred in 6% of cases. 
 
Erdmann et al. examined the spectrum of sarcomeric protein gene mutations in a German 
population [Erdmann 2003].  108 families were screened for sarcomeric protein gene 
mutations. 18 MYBPC3 mutations were identified in 20 families (18.5%). Little clinical 
data was reported, but this study demonstrated that MYBPC3 mutations are the most 
common genetic cause of HCM in this German population.  
 
Andersen et al. examined the spectrum of MYBPC3 mutations in a Danish population of 
81 consecutive patients referred to a tertiary centre in Copenhagen [Andersen 2004]. 
They also screened 7 other sarcomeric protein genes. 9 mutations were detected in 10 
families with one mutation present in two families (12.3% of the overall population).   35 
Three families were found to be double heterozygotes with mutations occurring in both 
MYBPC3 and MYH7 – a high proportion (30%). Ectopic messenger RNA (mRNA) 
expression was studied using peripheral blood leukocytes. At least 3 of the 9 mutations 
were felt likely to cause haploinsufficiency - as the product of translation would be so 
short as to prevent effective incorporation into the sarcomere.  
Jaaskelainen et al. screened 37 Finnish patients with HCM for MYBPC3 mutations and 
identified 4 disease causing mutations, one of which was a founder mutation (Gln1061X) 
[Jaaskelainen 2002]. Penetrance was variable within the 6 families with the founder 
mutation and clinical disease severity varied with most individuals having mild 
symptoms but one patient requiring cardiac transplantation. Although the data was 
unpublished they demonstrated that MYBPC3 mutations are the most prevalent cause of 
HCM in Finland accounting for 38% of cases of familial HCM. 
 
Van Driest et al. screened 389 HCM patients at the Mayo Clinic for mutations  in the 
sarcomeric protein genes MYBPC3, MYH7, MYL2, MYL3, TNNT2, TNNI3, TPM1 and 
ACTC [Van Driest 2004]. 46 MYBPC3 mutations were identified in 71 individuals. The 
overall prevalence of MYBPC3 mutations in this population was 18.3% with MYH7 
mutations accounting for 13.8%. Of the MYBPC3 mutations, 46% were missense, 33% 
frameshift, 13% nonsense, 7% splice site and 2% in-frame deletions. It should be noted 
however that the patient population at the Mayo Clinic is subject to referral bias as it is a 
tertiary referral surgical centre with a reputation for surgical myomectomy. Their HCM 
population is not necessarily representative of the broader population of HCM patients 
with and without LVOT obstruction therefore.   36 
Song et al. screened for mutations in MYBPC3, MYH7 and TNNT2 in a Chinese HCM 
population [Song 2005]. Of 100 patients with HCM, 25 mutations were found in 34 
families, including 9 MYBPC3 mutations (9%).  
 
Ingles et al examined the spectrum of sarcomeric mutations in an Australian HCM cohort 
[Ingles 2005]. Of 80 unrelated probands, 10 MYBPC3 mutations were identified in 11 
families (13.8%). 5% of the overall cohort had complex genetic status and were either 
double (MYH7 + MYBPC3) or compound (MYBPC3 + MYBPC3) heterozygotes.  
In summary, the prevalence of MYBPC3 mutations in unrelated, unselected patients with 
both familial and sporadic HCM ranges between 15 and 26.4%. MYBPC3 is the most 
commonly mutated gene in most series, and accounts for up to 50% of all identified 
mutations. In series of familial HCM this proportion is even higher. The clinical 
importance of MYBPC3 mutations therefore is their reported frequency in the overall 
HCM population, in that approximately 1 in 5 of the HCM population harbor a mutation 
in this gene.  
Penetrance of Disease 
In the first large scale study of its kind, Niimura et al. described the penetrance of disease 
and basic clinical characteristics of 228 gene positive individuals from 16 families with 
familial HCM in whom 12 different mutations in the MYBPC3 gene had been identified 
[Niimura 1998]. HCM was defined as a left ventricular wall thickness > 13mm in the 
absence of an identifiable cause. Mutations were considered pathogenic if absent in more 
than 200 chromosomes from control subjects, and were predicted to cause a biological 
effect. Of 212 gene carrying family members, 121 (57.1%) had evidence of clinical   37 
disease expression. Symptom severity, and the pattern and extent of hypertrophy were 
similar to those observed in patients with other HCM causing mutations (data not 
published). Ninety one individuals did not fulfill clinical diagnostic criteria for HCM, of 
which 53 were adults. The main findings of this study were therefore: 
1)  Disease penetrance in adult gene carriers was incomplete in the 16 families 
studied (70.9% overall and 57.1% in relatives assessed at family screening) 
2)  Disease penetrance appeared to increase with age 
3)  Prognosis appeared better than for families with MYH7 and TNNT2 mutations 
(data not published) 
The main limitation of this study is that the data is from a small number of families with 
familial HCM and over 50% of the data is derived from 3 large families sharing the same 
mutation. The possibility of referral bias also exists as such large families with multiple 
affected family members (while useful for linkage studies) are not necessarily 
representative of the broad population of HCM. The conclusions drawn suggesting that 
MYBPC3 disease is late-onset and benign are strongly worded and supported only by 
indirect or unpublished data. 
The impact of this paper however has been significant and long-lasting - current 
consensus guidelines recommend periodic screening throughout adulthood to detect 
patients with late-onset disease with major implications on resource allocation as well as 
causing potential anxiety for families attending for serial clinical examination [Maron 
2003a]. In addition, this study for the first time suggested that at least part of the 
phenotypic diversity seen by the clinician could be explained by genetic heterogeneity   38 
and that mutation specific advice could potentially play a role in managing patients and 
families with HCM.  
In smaller studies involving a limited number of families disease penetrance has varied. 
Moolman et al. reported disease penetrance of only 35% in a large South African family 
[Moolman 2000] while estimates of 90-100% were reported by other groups [Rottbauer 
1997][Moolman-Smook 1998][Doi 1999]. Disease penetrance was calculated at 71% in a 
large French cohort [Charron 1998a] and 86% in a large German/Turkish population 
[Erdmann 2001]. Two further studies estimated penetrance at 57% in a Danish cohort 
[Andersen 2004] and 76.9% in a Japanese cohort [Kubo 2005].  
While an average disease penetrance statistic is useful it doesn‟t reflect the variation 
between families – i.e. some families are fully penetrant [Anan 2001] whilst others are 
incompletely penetrant [Moolman 2000]. The factors which affect disease penetrance 
however are poorly understood. Niimura et al. suggested that disease penetrance was age-
related – i.e. penetrance increases with increasing age [Niimura 1998]. By calculating the 
proportion of individuals who have clinical disease from the total number of mutation 
carriers in a particular age group, it was shown that this proportion increased with 
increasing age, implying a relationship between disease penetrance and age. These data 
were derived from cross-sectional data and not from longitudinal follow-up however and 
provide only indirect evidence that disease may develop at any stage throughout life, and 
is not limited to adolescence and young adulthood as previously thought [Maron 1986b]. 
Anecdotal evidence of disease developing during adulthood has occasionally been 
demonstrated however [Maron 2001]. Maron et al. described the development of 
echocardiographic left ventricular hypertrophy in genotyped adults [Maron 2001]. Sixty   39 
one individuals from 7 families were found to be mutation carriers, of which 12 were 
clinically unaffected. 5 of these individuals were followed up prospectively, 3 (2 females, 
1 male) of which developed echocardiographic evidence of LVH during follow up at ages 
33, 35 and 42. One individual had an abnormal ECG on initial evaluation but the other 
two had normal ECGs at both the initial and follow-up evaluation. While this study did 
not determine the frequency of late-onset disease expression it did suggest that it can  
occur and they concluded that adult relatives without hypertrophy can no longer be 
reassured and require further follow up. These data support the theory that disease 
penetrance is age-related and that disease may develop in adults. 
 
Age at Diagnosis in Patients with MYBPC3 Mutations 
From the early studies examining the clinical spectrum of disease the general belief is 
that HCM develops in adolescence or early adulthood [Maron 1986b]. Following reports 
that MYBPC3 mutations may cause late-onset disease however [Niimura 1998] the 
relationship between age and disease onset has received considerable interest. Difficulty 
arises however because the age at clinical evaluation or first presentation does not 
necessarily correspond to the age at which the disease develops. Most studies which use a 
cross-sectional design are therefore unable to reliably identify at what age disease 
developed and unfortunately longitudinal studies are lacking.  
Assuming these limitations are constant however it is possible to compare the age at 
diagnosis or age at symptom onset for each sarcomeric gene.  
Estimates of mean age at diagnosis range from 33.0 years in a German population 
[Erdmann 2001] to 48.4 years in a Chinese population [Song 2005]. Wide confidence   40 
intervals of the mean exist however. In a study which pooled published data [Van Driest 
2005] from the United States, France, Germany, Sweden, Finland and Spain the overall 
age at diagnosis in patients with a MYBPC3 mutation was 37.9 which was statistically no 
different from any of the other major sarcomeric protein genes evaluated (MYH7 = 38.4, 
TNNT2 = 35.5, TNNI3 = 46.7, MYL2 = 35.1). The only longitudinal study to date which 
has reported disease development in adults demonstrated the development of hypertrophy 
de novo at the ages of 33, 35 and 42 [Maron 2001]. Disease development was defined in 
that study as the development of hypertrophy on transthoracic Echo which raises more 
complex questions regarding the definition of disease and whether ECG abnormalities 
constitute  disease development or not.  
Clinical Characteristics of Disease in Patients with MYBPC3 Mutations 
Although much interest has been focused towards genotype-phenotype correlations, 
clinical data from patients with MYBPC3 mutations in the published literature is limited. 
A broad spectrum of HCM phenotypes have been reported in association with MYBPC3 
mutations including neonatal heart failure [Lekanne-Deprez 2006], premature sudden 
cardiac death [Elliott 2000], severe outflow tract obstruction requiring surgical correction 
[Elliott 2006a], heart failure [Thaman 2005], thromboembolic stroke [Maron 2002] and 
mild disease with little restriction on daily activities [Niimura 1998].  
 
Although the first reports of MYBPC3 mutations were found in families with both 
sudden cardiac death and severe hypertrophy [Watkins 1995a], the concept that 
MYBPC3 mutations caused a benign and mild phenotype arose from the first large 
published genotype-phenotype correlation study [Niimura 1998]. Although the „clinical   41 
expression‟ of patients in this study was „similar to other genetic causes of hypertrophic 
cardiomyopathy‟ the calculated Kaplan-Meier survival curves suggested improved 
survival compared to TNNT2 or „malignant‟ MYH7 mutations (raw data unpublished). 
Once again it should be pointed out that over 50% of the data in this study was derived 
from 3 families with the same single base pair insertion mutation. No other clinical data 
was reported in this study.  
 
Charron et al described the phenotype of 33 individuals carrying a splice acceptor 
mutation in intron 20 of the MYBPC3 gene from 2 unrelated families [Charron 1998b]. 
Their clinical data were compared with data from 3 families with mutations in the MYH7 
gene. Maximal wall thickness was 17.6 +/- 6.3mm. No clinically important differences 
were apparent between the MYBPC3 individuals and the MYH7 individuals. Long term 
survival in patients with the MYBPC3 mutation was significantly reduced however, 
(survival to ages 20, 50 and 60 was 100%, 90% and 44% respectively) but better in 
comparison to a MYH7 mutation. It was not clear whether the prognosis was similar in 
both the families with the same MYBPC3 mutation or whether the premature, disease-
related deaths occurred in one of the two families. 
This same data was included in a larger study of MYBPC3 mutations by the same group 
later that year [Charron 1998a]. This study aimed to compare disease expression both 
between MYBPC3 and other mutations and also within the same gene (MYBPC3). 
Almost 50% of the data in this study however was that published in the earlier paper by 
the same group. In a comparison between pooled data from 69 patients with MYBPC3   42 
mutations and pooled data from 45 individuals with MYH7 mutations the important 
findings were: 
  1)  age of onset of symptoms was higher in patients with MYBPC3 mutation 
(40.9 +/- 19 years vs 34.6 +/- 17, p<0.02). 
  2)  mean age of death was higher in patients with MYBPC3 mutations (59.6 
+/- 10 years vs 38.5 +/- 16, p<0.002) 
  3)  Kaplan-Meier product-limit curves showed better prognosis for patients 
with MYBPC3 mutations (p<0.0001). 
These data, accepting the limitations noted above, were used to support the hypothesis 
that MYBPC3 mutations were associated with a relatively mild form of the disease. 
 
Erdmann et al. screened 110 patients with HCM for mutations in MYBPC3 [Erdman 
2001]. 13 mutations in 15 families were found and 14 other family members were found 
to be gene carriers (4 of which were unaffected). Two interesting observations were 
made. Firstly there was a trend towards protein truncation mutations causing earlier more 
severe disease than missense mutations, although this didn‟t reach statistical significance. 
Secondly, comparing the age of onset, severity of hypertrophy, and need for ICD 
implantation or myectomy with a group of 11 families with MYH7 mutations 
(unpublished data) there was no significant difference. 
 
Richard et al screened 197 index cases for sarcomeric protein gene mutations [Richard 
2003]. Disease causing mutations were identified in 124 index cases (64%). MYBPC3 
and MYH7 mutations accounted for 42% and 40% respectively. Of the 39 MYBPC3   43 
mutations, 26 were insertions/deletions, nonsense mutations or splice site mutations. The 
remainder were missense mutations. Index cases were classified into benign, intermediate 
or malignant groups according a history of adverse cardiac events within each family. 
MYBPC3 mutations were less prevalent in families with a malignant prognosis compared 
to MYH7 mutations, although MYBPC3 mutations were more common in patients with 
an intermediate prognosis than MYH7 mutations. MYBPC3 and MYH7 mutations were 
equally prevalent in families with a benign prognosis. Families with complex mutations 
(either compound or double heterozygotes or homozygotes) occurred in 6% of cases). 
 
In a large study of 389 HCM patients at the Mayo Clinic [Van Driest 2004], there were 
no apparent clinical differences between the different mutation types. Comparing 
MYBPC3 mutations to patients harboring MYH7, MYL2 or MYL3 mutations (thick 
filament) or ACTC, TNNT2, TNNI3 or TPM1 (thin filament) mutations there were no 
differences in terms in of age on onset, severity of hypertrophy, need for myectomy or 
ICD implantation. The mean age at diagnosis for patients with an MYBPC3 mutation was 
37.6 +/- 15 years. Interestingly 7% of the genotypes cohort (2.9% of the overall HCM 
cohort) had multiple mutations either as compound or double heterozygotes. These 
individuals were younger, more hypertrophied and required more interventions 
(myectomy or ICD) than any other subgroup. The HCM population at the Mayo Clinic 
however is subject to tertiary referral bias as it is specialist surgical centre offering 
surgical myectomy. Over 35% of patients had already undergone surgical myectomy 
prior to enrollment and 29% had an ICD. While screening this population has clear   44 
benefit in itself, the results cannot be widely extrapolated to the HCM population in 
general.  
 
Lekanne Deprez et al [Lekanne Deprez 2006] described two cases of fatal neonatal HCM, 
both of whom were compound heterozygotes for MYBPC3 mutations. The first child 
carried the paternally inherited splice site mutation c.1624+1G>A and the maternally 
inherited c.2373_2374insG mutation. The second child carried the paternally inherited 
nonsense mutation Arg943X and the maternally inherited Glu1096fsX92. No cardiac 
tissue was available for proteomic analysis but the authors felt that given the existing 
knowledge of the functional significance of at least one of the mutations and speculation 
as to the significance of the others it was likely that both patients could be considered as 
true MYBPC3 knockouts – i.e. no functional MYBPC3 protein expressed in the cardiac 
tissue - hence the severe phenotype. 
 
A number of smaller studies have reported clinical data on individuals or small families 
with MYBPC3 mutations with clinical data not dissimilar to that seen in the larger studies 
[Rottbauer 1997][Moolman-Smook 1998][Richard 1998][Doi 1999][Waldmuller 2003] 
[Morner 2003][Konno 2003a][Song 2005]. 
 
Summary: 
Over the last 10 years we have learned a great deal about the relationship between 
genotype and phenotype and the existing literature can be summarized as follows:   45 
  The prevalence of MYBPC3 mutations in genotyped HCM cohorts is 
approximately 15-25% 
  Disease penetrance is incomplete and ranges between 60-80% in most large series 
and may be age-related 
  Mean age at diagnosis from pooled data is approximately 37.9 years [Van Driest 
2005] 
  The pattern and degree of hypertrophy is highly variable 
  Prognosis is variable with both normal life expectancy and sudden premature 
death reported in different cohorts but few longitudinal data exist. While early 
studies suggested that MYBPC3 disease was associated with a more favorable 
prognosis, subsequent studies have observed a more varied clinical course. 
 
Despite the considerable interest in MYBPC3 related disease important questions 
therefore remain unanswered. This thesis attempts to add to the existing knowledge base 
by combining genetic and clinical evaluation of a large cohort of unselected individuals 
with MYBPC3 mutations; the specific aims and objectives of which are listed in the next 
section. 
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METHODS AND SUBJECTS   47 
Aims and Objectives 
 
The overall objective of this study was to provide new insights into the relationship 
between genotype and phenotype in patients with HCM and a mutation in the MYBPC3 
gene. 
More specifically this study aimed to: 
  Determine the penetrance of disease expression associated with MYBPC3 
mutations in a large unselected population 
  Describe the spectrum of disease and clinical disease severity in affected mutation 
carriers 
  Evaluate markers of early disease expression in a genotyped population 
  Determine the long-term effects of MYBPC3 mutations by serial clinical 
evaluation 
  Determine the spectrum of disease expression in families sharing an identical 
mutation 
Methodology 
Study Design 
A cross-sectional design was used to determine the penetrance of disease and clinical 
disease severity. A longitudinal cohort design was used to determine the long-term 
effects of MYBPC3 mutations in individuals with HCM. 
A number of individuals were involved in data collection: 
  Steve Page (SP) 
  Stavros Kounas (SK)   48 
  Brian Mist (BM) 
  Michael Christiansen (MC) 
  Paal Skytt Andersen (PSA) 
Case Selection 
A previous research programme at our unit had identified a cohort of 59 patients with 
HCM and a mutation in the MYBPC3 gene (BHF Programme Grant RG/2000009).  
These individuals had been identified from a larger cohort of 585 consecutive patients 
with HCM referred to our unit for evaluation who were systematically screened for 
genetic mutations in sarcomeric protein genes. All individuals fulfilled diagnostic criteria 
for HCM and the main reasons for referral included diagnostic clarification, clinical 
management, risk stratification and to facilitate family screening. 
 
Of these 585 individuals a total of 44 likely disease causing sequence variations were 
identified in 59 individuals. These individuals were either under active follow-up in our 
unit (n= 31) or had been seen previously and were now under local follow-up (n=28). 
Index cases were contacted (SP) to discuss whether they would be interested in 
participating in the study. They were provided with verbal and written information 
regarding the study (SP) and given time to consider whether they wished to take part. 
Participants were invited to attend the Inherited Cardiovascular Diseases Unit, The Heart 
Hospital, London for clinical evaluation. Participants were also asked to invite 1
st degree 
relatives to attend for clinical and genetic evaluation. If relatives were willing to 
participate they were provided with verbal and written information and written informed 
consent was obtained (SP - information sheet and consent form are found in the   49 
Appendix). If clinical evidence of was demonstrated in a 1
st degree relative, or if that 
individuals was found to be a mutation carrier, cascade screening was then offered in turn 
to their 1
st degree relatives and so on.  
Clinical Evaluation 
All individuals (index cases and relatives) were invited to attend the Inherited 
Cardiovascular Diseases Unit, The Heart Hospital, London for clinical evaluation. 
Demographic details and full clinical history were obtained and combined with a physical 
examination (SP). 
 
Blood pressure measurements were obtained using a mannual sphygmomanometer. 
Systolic pressure was defined as the pressure at which the first Korotkoff sound first 
appeared and the fifth Korotkov sound was used to define diastolic pressure.  
 
A 12-lead electrocardiogram recording (ECG) by either SP or a cardiac physiologist. 
ECG recordings were made in the supine position at rest. Standard bipolar limb lead 
electrodes were connected to the right arm, left arm and left leg with a neutral electrode 
attached to the right leg. Augmented limb lead electrodes were recorded using Wilson‟s 
central terminal. Chest leads were positioned in the following sequence.  
  V1  4
th intercostals space just right of the sternum 
  V2  4
th intercostals space just left of the sternum 
  V3  midway between V2 and V4 
  V4  apex 
  V5  5
th intercostals space anterior axillary line   50 
  V6  5
th intercostals space mid axillary line 
A paper spead of 25mm/s and calibration of 10mm/mV was used. 
ECGs were analysed by SP for the following: 
  Rhythm 
  Atrial morphology - biphasic P wave in V1 with terminal deflection > 1mm and 
>0.04s duration 
  PR interval 
  Presence or absence of Q waves (a pathological Q wave was defined as a negative 
deflection with a duration >40ms and greater than 1/3 ensuing R wave height, and 
a non-pathological defined as a negative deflection with a duration < 40ms and 
less than 1/3 ensuing R wave height). 
  QRS duration 
  Presence of left ventricular hypertrophy using Romhilt Estes score, Sokolow 
Lyon criteria and Cornell criteria (Table 6 for definitions). 
  T wave morphology – either flat or inverted below the isoelectric line 
Table 6   Definitions used for ECG LVH Measurements 
 
Parameter  Definition  Score 
Romhilt Estes Score  Voltage Criteria (any of): 
R or S in limb lead > 20mm 
S in V1 or V2 > 30mm                                   3 points 
R in V5 or V6 > 30mm 
ST-T Abnormalities 
With Digoxin                                                  1 point 
Without Digoxin                                             3 points 
Left Atrial Enlargement in V1                                       3 points 
Left axis deviation                                                          2 points 
QRS duration > 90ms                                                     1 point 
Intrinsicoid deflection in V5 or V6 > 50ms                   1 point 
Scored out of 14. Scores 
> 4 considered to 
represent LVH 
Sokolow Lyon Criteria  S in V1 + R in V5 or V6 > 35 mm  Yes or No 
Cornell Criteria  S in V3 + R in aVL > 24 mm (men) 
S in V3 + R in aVL > 20 mm (women) 
Yes or No 
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Individuals also had a transthoracic echocardiogram using a dedicated departmental 
protocol. Studies were performed on Vivid 7 machines (GE Healthcare, Little Chalfont, 
UK) using a 3.5Hz probe. In addition to standard views and measurements [Gardin 
2002], the following measurements were made: maximal left ventricular wall thickness 
measurements at 12, 3, 6 and 9-o‟clock positions at mitral valve, papillary muscle and 
apical levels (12- and 6 o‟clock only) using leading-edge to leading-edge technique.  
Right ventricular wall thickness (also using leading-edge to leading-edge technique) was 
assessed in the parasternal long axis view, the parasternal short axis view at the level of 
the RVOT, the right ventricular free wall in the apical 4-chamber view and the free wall 
in the sub-costal view [Foale 1986][McKenna 1988].  Pulsed tissue Doppler imaging was 
used to record the systolic, early and late diastolic velocities at mitral valve annulus at the 
septum and lateral wall (in the apical 4-chamber view) and anterior and inferior walls (in 
the apical 2-chamber view) when possible. Colour flow mapping was used to detect flow 
acceleration in the LV cavity and pulsed wave and continuous wave Doppler was used to 
estimate peak velocity in the LV outflow tract and mid-cavity. If no outflow tract 
obstruction was noted at rest the measurements would be repeated following a Valsalva 
manoeuvre. Left atrial diameter was recorded in the parasternal long-axis view and apical 
4-chamber view. The right ventricle was carefully assessed for evidence of hypertrophy 
and pulmonary artery systolic pressures were calculated. Transthoracic echo studies were 
performed by highly trained echocardiographers with a specialist interest in imaging 
patients with cardiomyopathy. Studies were reviewed off-line by SP and SK.   52 
When possible individuals also underwent metabolic exercise testing using a bicycle 
ramp protocol. Tests were symptom limited and supervised by a trained exercise 
physiologist (BM). Gas exchange data, symptoms, arrhythmias and blood pressure 
response were recorded at baseline and throughout the exercise protocol into the recovery 
phase. A failure of the systolic blood pressure to rise at least 25mmHg above baseline 
was considered an abnormal blood pressure response (ABPR) [Elliott 2000]. 
Individuals underwent 24 hour ambulatory Holter monitoring if symptoms of palpitations 
or syncope were reported, or routinely in individuals with HCM as part of risk 
stratification for sudden cardiac death. Data was analysed manually by a cardiac 
physiologist and atrial and ventricular premature complexes, supraventricular and 
ventricular arrhythmias, bradycardia, mean, minimum and maximum heart rate were 
recorded. Patients were supplied with a symptom diary card to allow correlation of 
symptoms to arrhythmias. Non-sustained ventricular tachycardia (NSVT) was defined as 
three or more consecutive beats with a ventricular origin at a rate greater or equal to 120 
beats per minute. 
 
Other cardiac investigations such as coronary angiography, cardiac magnetic resonance 
imaging and myocardial perfusion imaging were performed on the basis of clinical need. 
If individuals were unable to travel to The Heart Hospital local arrangements for clinical 
screening were made with investigations (ECG and Echo) forwarded for analysis (SP). 
Clinical Management 
All individuals fulfilling diagnostic criteria for HCM were managed according to Clinical 
Expert Consensus Documents [Maron 2003a] and local clinical expertise. The main   53 
principles of management were to reduce symptoms and to prevent sudden complications 
such as sudden cardiac death and stroke. Gradient reduction therapies included beta-
blockers, calcium channel blockers, disopyramide, alcohol septal ablation, surgical left 
ventricular myomectomy and dual chamber pacemaker implantation. Risk factors for 
sudden cardiac death were determined systematically in all individuals with HCM. Major 
risk factors were: previous cardiac arrest, unexplained syncope, family history of sudden 
cardiac death, left ventricular wall thickness greater than 30mm, non-sustained VT on 
Holter monitoring and an abnormal blood pressure response on bicycle exercise testing. 
In patients with 2 or more risk factors, consideration for ICD implantation was made. In 
those with only 1 risk factor, decisions were made on an individual basis. Patients felt to 
be at increased risk of thromboembolic stroke were considered for anticoagulation with 
Warfarin. Risk factors included atrial fibrillation, left atrial diameter greater than 50mm 
in the parasternal long axis view, heart failure and increasing age. 
Genetic Evaluation 
The cohort of index cases had been previously identified from a larger cohort of 585 
individuals fulfilling diagnostic criteria for HCM referred to our unit for evaluation. Each 
individual had provided a blood sample for mutation analysis. Each sample was screened 
for mutations in the following genes:  
  MYBPC3 
  MYH7 
  TNNT2 
  TNNI3 
  MYL2   54 
  MYL3 
  TPM1 
  PRAKG2 (if clinically indicated – premature conduction tissue disease or pseudo 
pre-excitation pattern on ECG) 
  GLA (if clinically indicated – concentric hypertrophy, X-linked inheritance, 
associated non-cardiac symptoms such as angiokeratoderma and anhydrosis) 
All coding regions were screened systematically for sequence variations by direct 
sequencing and fluorescent (F)-SSCP analysis by MC, PSA and RFH according to 
standard techniques. All genes were screened even once a sequence variation had been 
identified. Sequence variations were considered to be pathogenic mutations on the basis 
of the following criteria with reference to published criteria [Cotton 1998]. 
  The sequence variation cosegregated with clinical disease within the family 
(determined from clinical evaluation performed by SP) 
  The sequence variation occurred within a region of conserved DNA across 
different species (for missense mutations) 
  The sequence variation was absent in commercially available control alleles 
  The sequence variation was predicted to cause a mutated protein with biological 
effect either confirmed by RNA functional studies or by inference in the case of 
non-sense or frameshift mutations 
Relatives were invited to provide a venous blood sample for mutation analysis for the 
family mutation. No other sarcomeric protein genes were screened in relatives. Relatives 
were counselled by either a clinical genetics counsellor or by SP. Counselling was 
performed face to face when possible or over the telephone if the patient was unable to   55 
travel to The Heart Hospital. Relatives were provided with both verbal and written 
information (see Appendix) and informed written consent was obtained.  
 
Venous blood samples from relatives were collected (SP) into 2x4.5ml EDTA tubes 
which were immediately refrigerated and subsequently stored at -80 °C for subsequent 
batched DNA analysis. Samples were analysed for the known family mutation only and 
an individual could therefore either be wild type or a mutation carrier. 
If relatives were unable to attend The Heart Hospital individuals were offered genetic 
screening remotely with verbal and written information provided and genetic counselling 
performed by telephone. Venous blood samples were collected locally, and posted to The 
Heart Hospital for further processing. 
 
Definitions 
A number of terms are used frequently in this thesis and are defined below. 
A diagnosis of HCM was defined by ventricular hypertrophy greater or equal to 13mm in 
the absence of a haemodynamic cause [McKenna 1997] 
An index case was defined as an individual fulfilling diagnostic criteria for HCM, from 
the original cohort in whom a MYBPC3 mutation had been identified.  
An affected mutation carrier was an individual who carried the family mutation and had 
echocardiographic hypertrophy with a maximal wall thickness of at least 13mm. 
An unaffected mutation carrier was an individual who carried the family mutation but 
had a maximal wall thickness of less than 13mm.    56 
Sudden cardiac death was defined as death occurring within 1 hour of the onset of new 
symptoms, or nocturnal death without an antecedent history of worsening symptoms. 
A family history of sudden cardiac death was defined as sudden cardiac death in two or 
more first degree relatives less than 40 years old. 
Disease penetrance was defined as the proportion of mutation carriers who demonstrated 
evidence of clinical disease expression sufficient to fulfil diagnostic criteria for HCM 
Statistics 
Data was recorded using Microsoft Excel spreadsheets and statistical analysis was 
performed using SPSS software. Mean values with standard deviations were calculated 
for continuous variables with ranges given where appropriate. Comparison of means 
between groups was made using Student‟s t-test and ANOVA when more than two 
groups were being compared, assuming the data was normally distributed. For categorical 
variables the Chi-square test was used. A p-value of < 0.05 was considered statistically 
significant.   57 
Ethical Approval and Funding 
This clinical study was an observational, cross-sectional study in which the selection of 
patients and clinical management decisions were based upon clinical need rather than 
specifically for research. Local Ethical Committee approval was obtained as part of an 
ongoing larger British Heart Foundation Programme Grant (BHF Programme Grant 
RG/2000009) into genotype-phenotype correlations in HCM.  
 
Ethical approval was obtained for the larger study „Hypertrophic cardiomyopathy 
(HCM): Clinical and Genetic Investigation of a Hereditary Heart Disease‟. This ethical 
approval was obtained in 2003 by Professor WJ McKenna – approved by the 
Wandsworth Local Research Ethics Committee, South London REC, St George‟s 
Hospital, London (Ref 01.78.10). Following the departmental move to the Heart Hospital, 
UCLH, London, ethical approval was also sought from the UCLH REC (Ref 03/0196).  
 
Participation in the study was voluntary and individuals could withdraw from the study at 
any stage. All individuals providing blood for DNA analysis provided written informed 
consent. Funding for this study was provided by the British Heart Foundation who 
awarded a Junior Research Fellowship to SP.  58 
 
THE SPECTRUM OF MYBPC3 MUTATIONS IN FAMILIES 
WITH HCM 
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Introduction 
 
HCM is characterised by an autosomal dominant pattern of inheritance with a mutation in 
one of the sarcomeric protein genes identified in up to 60% of individuals [Richard 
2003]. For a complete list of genes associated with HCM see Table 1. The most common 
sarcomeric protein gene in which mutations are found is MYBPC3, accounting for 
approximately 20% of HCM cohorts [Van Driest 2005]. Most mutations are novel and 
„private‟ although founder mutations have been identified in some populations 
[Moolman-Smook 1999][Waldmuller 2003][Richard 2003][Alders 2003][Konno 
2003][Jaaskelainen 2004][Kubo 2005]. 
 
In most large series missense and insertions/deletions account for the majority of 
MYBPC3 mutations, with fewer nonsense and splice site mutations [Richard 
2003][Erdman 2003][Van Driest 2004]. 
 
In this section the spectrum of mutation identified in this study are described. 
 
Methods 
 
A previous study, supported by the British Heart Foundation (BHF Programme Grant 
RG/2000009) systematically screened a cohort of 585 consecutive individuals fulfilling 
diagnostic criteria for HCM for mutations in sarcomeric protein genes. DNA analysis was 
performed in Copenhagen, at the Statens Serum Institute by PSA and MC. 
DNA sequencing techniques and screening methods are described in the Methods 
Section.    60 
Mutations located in the flanking introns of the MYBPC3 micro-exons were examined 
using in silico methods. Ectopic expression of mRNA in blood leukocytes in the 
respective patients was examined using reverse transcription-PCR. 
Results 
Index cases 
A total of 44 MYBPC3 mutations were identified in 59 of 585 index cases (10.1%) which 
were believed to be disease causing. These mutations are described in Table 7. Of the 44 
mutations identified 28 were novel (63.6%).  
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Table 7   Disease Causing MYBPC3 Mutations in 59 Index Cases with HCM 
 
Mutation Type  Mutation Description 
Nonsense (4 mutations in 5 families)  Q425X 
Q969X * 
K1055X 
R943X 
Deletions/Insertions (10 in 11 families)  g7040_7041delTT 
g14271delC 
g14274delC 
g15919insG 
g16225delG 
g16190_16196delGCGTCTA 
g20350insT * 
g14291insA 
698delC 
g18567delCT  
Missense (15 in 26 families)  R502W * 
R502Q * 
E258K * 
G341R 
R495G * 
P873Q 
E542Q 
D605N 
G490R 
R820Q 
T750M 
G148R 
F1177L 
C1266Y 
T957S 
Intronic (9 in 11 families)  IVS20-2A>G 
IVS7+1G>A 
IVS13-2A>G 
IVS14-13G>A 
IVS1-2A>G 
IVS27+1G>A 
IVS13-19G>A * 
IVS17+4A>T 
IVS9-36G>A  
Complex Genetic Status (6 in 6 families)  MYBPC3 G148R AND GLA N215S 
MYBPC3 IVS14-13G>A* AND MYH7 T1854M 
MYBPC3 R502W * AND MYH7 N602S 
MYBPC3 G490R AND MYBPC3 Q642X 
MYBPC3 V1125M AND MYBPC3 IVS9-1G>C 
MYBPC3 IVS18+7G>A AND MYBPC3 D880D 
Sequence Variations of Uncertain Significance (9 in 9 families)  IVS26-52G>A 
IVS1-2A>G  
IVS20-23A>G  
IVS16-26C>G 
IVS8-37C>T  
IVS25-10C>T  
IVS2-51 T>C 
g15096C>T, G758G 
g21033C>T, I1193I 
   
* - Mutation found in more than 1 family 
 
A further 9 sequence variations were identified in which the pathogenicity was uncertain 
or unlikely. These mutations either did not co-segregate with clinical disease or were of 
uncertain functional significance. Data from these families was excluded from analysis.   62 
 
Mutations were grouped by type (Figure 2). The most common type were missense 
mutations (26, 44%). Insertions or deletions accounted for 11 (19%). Five (8%) were 
nonsense mutations producing a premature stop codon. Eleven (19%) were intronic 
mutations. Interestingly 10% of the genotyped cohort had complex genetic status. In one 
index case, mutations were identified in MYBPC3 and GLA. This individual had clinical 
features consistent with Anderson Fabry disease with other similarly affected individuals 
on the maternal side of the family. The MYBPC3 mutation had been inherited from the 
paternal side of the family. In 2 families, mutations were identified in MYBPC3 and 
MYH7 (double heterozygotes) and in 3 families two mutations were identified in 
MYBPC3 (compound heterozygotes). One of these families had both an IVS18+7G>A 
mutation and a single base substitution (g17675 C>T) resulting in D880D. The 
significance of this second sequence variation is uncertain and it was not possible to 
study the functional consequences of this mutation as no relatives were found to be 
carriers of this mutation alone. 
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Figure 2    Spectrum of mutations in 59 index cases 
Missense, 26, 44%
Insertion/Deletion, 
11, 19%
Intronic, 11, 19%
Nonsense, 5, 8%
Complex Genetic 
Status, 6, 10%
 
 
 
A total of seven mutations were discovered in the introns flanking the two micro-exons 
10 and 14, but none were found in introns flanking exon 11.  
Familial Mutation Analysis 
In addition to the 59 index cases, familial mutation analysis identified a further 111 
mutation carriers and 118 relatives who were wild type for the family mutation. The total 
number of mutation carriers (index cases and relatives) was 170. 
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Discussion 
 
The main findings can be summarised as follows: 
  The prevalence of MYBPC3 mutations in our HCM cohort was 10.1% 
  More than 60% were novel mutations 
  Missense mutations were the most frequent accounting for 44% of all mutations 
identified 
  The previously described R502W mutation was found in 9 families with evidence 
of a founder effect following haplotype analysis 
  Intronic mutations were common and accounted for 18.6% of mutations identified 
  Complex genetic status was common and occurred in 10.2% of index cases with 
an MYBPC3 mutation 
 
The spectrum of mutation type seen in this study is broadly similar to that seen in other 
cohorts of MYBPC3 mutations  (Figure 3) [Richard 2003][Erdman 2003][Van Driest 
2004]. 
 
A pathogenic mutation in MYBPC3 was identified in 10.1% of the overall HCM cohort 
which is slightly lower than previously reported [Van Driest 2005]. This may represent 
differences in mutation detection methods, although in this study all exons (including 3 
micro-exons) and intronic sequences were analysed. It may be that the strict criteria used 
in this study to define a disease causing mutation led to a lower yield than in previously 
published data.  
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Similar to previous series, most identified mutations were novel. The phenomenon of so-
called „private mutations‟ lends added complexity to the clinical genetics of HCM, as 
mutation specific data are usually lacking. Consequently „proof of pathogenicity‟ 
becomes more challenging and providing mutation specific advice when counseling 
families becomes impossible. This phenomenon is not specific to MYBPC3 mutations 
however.  
The finding of a founder effect in 9 families with the R502W mutation is interesting as 
this is the first founder mutation to be described in an UK population. Founder MYBPC3 
mutations have been described previously in HCM cohorts, including a highly prevalent 
2373insG mutation in the Dutch population, found in 23.2% of all HCM index cases 
[Alders 2003). Identifying several families with an identical mutation provides a unique 
opportunity to examine phenotypic heterogeneity having controlled for a specific 
mutation. This data is discussed later in Chapter: Disease Expression in Families Sharing 
Identical Mutations. 
 
Of note was a high proportion of individuals with complex genetic status with both 
double heterozygotes and compound heterozygotes seen. This has major implications for 
DNA screening strategies - a high incidence of complex genetic status affects the 
accuracy and reliability of genetic predictive testing and has implications for calculating 
the risk of inheriting a mutation for children in families with two pathogenic mutations. 
Whether the mutations are compound or double and whether the mutations occur on the 
same allele (for compound mutations) can greatly affect the risk that should be discussed 
with the parents when family planning. Furthermore, a more severe phenotype has been   66 
described in certain individuals with complex genetic status [Van Driest 2004][Richard 
2003] including neonatal hypertrophy [Lekanne Deprez 2006] and severe hypertrophy in 
a female homozygous for a A627V missense mutation [Garcia-Castro 2005]. The high 
incidence of complex genetic status in this study supports a protocol of full sequencing of 
all sarcomeric protein genes [Ingles 2005], rather than targeted selective DNA screening 
as advocated by some [Girolami 2006]. This concept is further supported by the novel 
identification of pathogenic mutations in the intronic flanking regions of the two micro-
exons 10 and 14 [Frank-Hansen 2008]. 
 
In summary the spectrum of mutations in this cohort is broadly similar to previous studies 
but highlights the wide genetic heterogeneity typically seen in HCM. The remainder of 
this thesis describes in detail the clinical characterisation of index cases and their families 
with the MYBPC3 mutations identified during this study. 
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Figure 3    Spectrum of MYBPC3 mutations in different cohorts 
Spectrum of Mutations (data from this study)
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DISEASE PENETRANCE, AGE AND GENDER IN 
FAMILIES WITH MYBPC3 MUTATIONS   69 
Introduction 
 
In common with many autosomal dominant conditions, disease expression in HCM is 
highly variable, and for most reported mutations disease penetrance is incomplete (i.e. 
not all mutation carriers manifest clinical disease) [Niimura 1998][Charron 1998a]. As 
described in the Introduction, estimates of disease penetrance in families with MYBPC3 
mutations vary but in most studies of reasonable size, range between 57% [Andersen 
2004] and 86% [Erdmann 2001].  
The factors that influence disease penetrance are poorly understood. Niimura et al. 
suggested that low penetrance was characteristic of MYBPC3 mutations per se, and may 
be age-dependent [Niimura 1998]. Historically HCM has been considered to be a disease 
that develops in adolescence and early adulthood [Maron 1986b], but in a cross-sectional 
study of families with MYBPC3 mutations, Niimura et al. observed a linear relationship 
between increasing age and increasing disease penetrance with almost complete 
penetrance by the 7
th decade [Niimura 1998]. This was in contrast to families with 
mutations in MYH7 and TNNT2 who appeared to have almost complete penetrance by 
the 4
th decade. This observation provided indirect evidence that disease can develop in 
adulthood, and so called „late-onset‟ disease was felt to be a phenomenon associated only 
with MYBPC3 mutations. Cross-sectional studies however are inherently limited in their 
ability to identify „late-onset‟ disease rather than „late-diagnosis‟ – a distinction with 
important implications for how clinicians screen HCM families . Another study suggested 
that MYBPC3 mutations are predominant in a group of patients with disease diagnosed > 
40 years, although the proportion was not dissimilar to the overall genotyped HCM 
population (16%) [Niimura 2002].    70 
The relationship between penetrance and gender is unknown. Despite an autosomal 
dominant pattern of inheritance, most HCM cohorts demonstrate a slight male 
predominance of approximately 3:2, consistent amongst cohorts from different genetic 
and racial backgrounds [Maron 2003][Olivotto 2005]. Although data on gender 
differences in HCM are limited, a number of observations have been reported including: 
1) an inverse relationship between age and maximal wall thickness has been reported in 
females [Maron 2003a], 2) females are older at first diagnosis [Maron 2003b], 3) females 
are more symptomatic and have a higher prevalence of left ventricular outflow tract 
obstruction [Olivotto 2005], 4) overall mortality and risk of sudden cardiac death appear 
similar between males and females however [Elliott 2000]. If gender differences in 
clinical disease expression do exist it is possible that gender plays a role in determining 
disease penetrance. 
 
This section examines disease penetrance with particular reference to age and gender. 
 
Methods 
 
59 index cases found to have mutations in MYBPC3 were evaluated. Relatives were 
invited for clinical and genetic evaluation as described in Chapter 2. HCM was defined in 
relatives as unexplained LVH (maximal wall thickness ≥13mm) [McKenna 1997]. 
Disease penetrance was calculated as the proportion of all mutation carriers who fulfilled 
diagnostic criteria for HCM (index cases and relatives).  
Clinical markers of disease expression (including prevalence of symptoms and 
echocardiographic parameters) were compared between males and females. The   71 
relationship between disease penetrance and age was also examined. Age at diagnosis 
was defined as the age (to the nearest year) at which a diagnosis of HCM was first made, 
rather than age at initial evaluation at our institution.  
 
Comparisons between groups were made using ANOVA or independent Students t-test 
for continuous variables and Chi-square test for categorical data. A p-value of <0.05 was 
considered statistically significant. 
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Results 
 
Disease Penetrance 
In addition to the 59 index cases, family screening identified a further 111 mutation 
carriers and 119 relatives who were negative for the family mutation. The total number of 
mutation carriers (index cases and relatives) was 170. At the last clinical evaluation, 98 
fulfilled diagnostic criteria for HCM and 72 were unaffected mutation carriers. Disease 
penetrance for the overall cohort was therefore 58% (Figure 4). 
Figure 4    Proportion of individuals fulfilling diagnostic criteria in 170 mutation carriers 
Proportion of Mutation Carriers with HCM
72 / 42%
98 / 58%
Unaffected
HCM
 
 
Family screening identified an additional 39 affected mutation carriers from 234 family 
members screened (a yield of 16.7%).    73 
Disease Penetrance and Age 
The relationship between disease penetrance and age at initial evaluation is shown in 
Figure 5.  
Figure 5    Disease Penetrance According to Age in 170 Mutation Carriers 
 
Grouped Age at Diagnosis or First Assessment (Years)
70+ 60-69 50-59 40-49 30-39 20-29 10-19 0-9
D
i
s
e
a
s
e
 
P
e
n
e
t
r
a
n
c
e
 
(
%
)
100
90
80
70
60
50
40
30
20
10
0
 
 
Disease penetrance appeared to increase with age until the 6
th decade providing indirect 
but supportive evidence that the diagnostic hallmark of HCM (echocardiographic 
evidence of ventricular hypertrophy) may develop in adulthood. Interestingly, disease 
penetrance appears to plateau (or even fall in the 7
th and 8
th decades – perhaps due to 
reduced survival in affected individuals), demonstrating that a proportion of mutation 
carriers will never develop clinical evidence of disease. Of the 7 unaffected mutation 
carriers aged ≥70 years the spectrum of mutations was as follows: 1 nonsense, 1 deletion,   74 
3 missense, 1 intronic and 1 compound heterozygote – i.e. a broad spectrum of mutation 
types is demonstrated in this sub-group of individuals. When disease penetrance is 
defined in terms of an abnormal ECG (defined as either RE score >4, abnormal T wave 
inversion or abnormal Q waves), rather than echocardiographic LVH, it is apparent that 
ECG abnormalities pre-date the development of LVH on echocardiography and using 
ECG criteria for evidence of clinical disease expression is more sensitive than criteria 
based upon echocardiography alone (Figure 6). It can be seen that disease penetrance, as 
defined by an abnormal ECG, is also incomplete - 71.2% overall – i.e. a proportion of 
mutation carriers (approximately 30%) have a normal ECG even at advanced age. 
 
Figure 6    Disease Penetrance According to ECG or Echo Criteria 
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Of 98 affected mutation carriers only 8 were diagnosed before the age of 20 years (8.2%) 
(Figure 7) – i.e. over 90% of individuals were diagnosed after the age of 20 years. Indeed   75 
Figure 7 demonstrates that HCM related to MYBPC3 mutations can be diagnosed in any 
decade of life. Of the 4 individuals diagnosed age 70+, 3 were diagnosed in their 70s and 
1 in his 80s.  
Figure 7    Age at Diagnosis in 98 Affected Mutation Carriers 
Age at Diagnosis in 98 Affected Mutation Carriers
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If all those diagnosed at family screening (in this group, age is dependent on the strategy 
of the screening hospital) were excluded, 4 of 49 (8.2%) were diagnosed before age 20 
years and 91.8% of index cases were diagnosed after the age of 20 years (Figure 8).   76 
Figure 8    Age at Diagnosis in 49 Affected Mutation Carriers Excluding those Diagnosed at 
Family Screening   
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When affected individuals were grouped into early-diagnosis (< 40 years) and late-
diagnosis (≥ 40 years) there were no apparent important clinical differences in terms of 
septal thickness, maximal wall thickness, LV cavity size, or % symptomatic (Table 8). 
The age of 40 years was chosen as it has been used previously in studies to define early-
onset and late-onset disease [Niimura 2002]. The data was also analysed defining late-
onset disease as > 30 years, > 50 years, > 60 years and > 70 years. No significant 
differences were observed however in any of the variables shown in Table 8, and it was 
not possible to identify a clinically useful definition of late-onset disease. 
 
The prevalence of confirmed familial disease (defined as at least 1 other affected relative) 
was no more common in those with early-diagnosis (76.7% v 69.1, p=0.4).   77 
Table 8   Comparison between individuals with early and late diagnosis 
Parameter  Early Diagnosis (< 40 Years)  Late Diagnosis (≥40 
Years) 
P – value 
Number of Individuals  43  55  - 
Mean Age at Diagnosis (years)  23.0 +/- 7.8  53.2 +/- 10.1  0.000 
Male (%)  65.1  54.5  χ2 = 1.1, 1df, p=0.291 
Symptomatic (%)  60.0  59.2  χ2 = 0.006, 1 df, p=0.938 
Echo parameters       
LA diameter (mm)  40.3 +/- 8.4  42.2 +/- 6.2  0.220 
LVEDD (mm)  42.6 +/- 7.3  44.7 +/- 6.0  0.136 
LVESD (mm)  24.5 +/- 6.3  27.2 +/- 6.4  0.052 
FS (%)  43.9 +/- 9.5  41.6 +/- 8.6  0.384 
IVSd (mm)  17.7 +/- 6.0  18.0 +/- 4.8  0.782 
PWd (mm)  9.8 +/- 2.4  10.8 +/- 2.5  0.059 
MWT (mm)  18.6 +/- 5.8  18.7 +/- 5.2  0.922 
Mean number of Risk factors  0.9 +/- 0.8  0.8 +/- 0.8  0.490 
Confirmed familial disease (%)  76.7  69.1  χ2 = 0.7, 1 df, p=0.4 
       
 
In three individuals disease developed during prospective follow up. H610.1 (mutation 
Cys698del) and H62.2 (mutation Arg502Gln) were diagnosed shortly after initial 
assessment at ages 13 and 14 respectively. Only H610.8 (mutation 698delC) clearly 
developed HCM as an adult which was diagnosed age 53. He was first assessed in 1993, 
age 40, as part of family screening and had a normal ECG and Echo at that stage. In 
2006, age 53, he underwent a routine medical. ECG showed LVH with widespread 
repolarisation abnormalities and a Romhilt Estes score of 7. Transthoracic Echo showed 
asymmetrical septal hypertrophy with a maximal wall thickness of 15mm. He had had no 
interim assessment in between so the age at which LVH developed is not precisely 
known, but occurred between the ages 40 and 53. He was not known to be hypertensive 
and although fit and active, had never undergone sustained athletic training. 
 
Disease Penetrance and Gender 
Of 170 mutation carriers, 88 (51.8%) were male and 82 (48.2%) were female. Disease 
penetrance was higher in males than in females (65.9% v 48.8%, χ
2=5.35, 1df, p= 0.021) 
(Figure 9). Mean age at diagnosis in affected individuals was no different between males   78 
and females (40.6 +/- 15.1 years v 43.3 +/- 17.2, p=0.411). When all 170 mutation 
carriers are considered, males have greater LA diameter (40.7 v 36.5, p=0.001), greater 
LV cavity dimensions (LVEDD 46.4 v 43.1, p=0.001, LVESD 28.9 v 26.1, p=0.006) and 
greater degrees of hypertrophy (septal thickness 15.5 v 12.7, p=0.004, maximal wall 
thickness 16.1 v 13.6, p=0.012) (Table 9). When only affected individuals are considered 
however these gender differences no longer exist and are therefore explained by the 
higher disease penetrance in males.  
Table 9   Gender Differences in 170 Mutation Carriers 
Parameter  Male  Female  p Value 
Number of Patients  88  82  - 
Age at diagnosis (affected only, years)  40.6 +/- 15.1  43.3 +/- 17.2  0.411 
% Affected  65.9  48.8  0.021 
% Symptomatic  38.6  36.8  χ2 = 0.049, 1 df, p=0.824 
% Predicted VO2  78.9 +/- 23.0  75.4 +/- 3.2  0.484 
Echocardiographic parameters       
LA dimension (mm)  40.7 +/- 7.2  36.5 +/- 7.4  0.001 
LVEDD (mm)  46.4 +/- 6.5  43.1 +/- 6.1  0.001 
LVESD (mm)  28.9 +/- 6.1  26.1 +/- 5.7  0.006 
FS (%)  39.2 +/- 7.8  40.3 +/- 9.5  0.517 
Septal thickness (mm)  15.5 +/- 6.0  12.7 +/- 5.9  0.004 
Posterior wall thickness (mm)  10.0 +/- 2.0  9.1 +/- 2.8  0.024 
Maximal wall thickness (mm)  16.1 +/- 6.2  13.6 +/- 6.2  0.012 
       
   79 
 
Figure 9    Disease Penetrance in Males and Females 
 
Another way of looking at the data is calculating the proportion of individuals fulfilling 
diagnostic criteria for HCM (maximal wall thickness ≥13mm) for grouped age at 
diagnosis or initial assessment (Figure 10). It can be seen that in all age groups disease 
penetrance is incomplete. 
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Figure 10    Number of individuals in each age group showing proportion fulfilling 
diagnostic criteria for HCM 
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Disease Penetrance and  Mutation Type 
Disease penetrance was incomplete for all mutation types (Figure 11). Of 38 families 
with at least 2 mutation carriers in adults aged 18 years or more, 33 showed incomplete 
penetrance and 5 showed fully penetrant disease (2 missense, 1 intronic, 2 complex 
genetic status). Disease penetrance was also incomplete in families with complex genetic 
status - 13 individuals inherited two possible disease causing mutations, of which 11 
fulfilled diagnostic criteria for HCM (84.6%). Two individuals were unaffected – one 
was a 17 year old female with a 2 base-pair deletion and cryptic splice site mutation in   81 
MYBPC3. The other was a 51 year old female with missense mutations in MYBPC3 and 
MYH7.  
 
Figure 11    Disease penetrance according to mutation type 
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Penetrance appeared to be independent of the specific mutation. A total of 8 families 
shared the same R502W mutation: of the 6 families with at least 2 mutation carriers, 4 
families had incomplete penetrance while in 2 families all mutation carriers examined 
fulfilled diagnostic criteria for HCM (Figure 12).     82 
Figure 12    Disease penetrance in 25 R502W mutation carriers 
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Discussion 
 
The main findings relating to disease penetrance can be summarized as follows: 
1.  Disease penetrance is incomplete (57.6%) in this cohort of 170 MYBPC3 
mutations carriers 
2.  Disease penetrance is related to age, however… 
3.  Incomplete penetrance is seen in all groups even at advanced age 
4.  Disease penetrance is independent of mutation type 
5.  Disease penetrance is independent of specific mutation 
6.  Disease penetrance is higher in males than in females 
 
Several important conclusions can be drawn from these data. 
Previous data have suggested that disease penetrance increases with age, and is complete 
by the later decades, with no plateau effect, implying that clinical evidence of disease will 
develop at some stage during an individual‟s lifetime [Niimura 1998]. While a 
relationship between increasing age and increased disease penetrance was also seen in 
this study, in contrast to previous data, a plateau effect (around the 5
th or 6
th decade) was 
observed suggesting that up to 25-30% of individuals may never develop clinical 
evidence of disease even at advanced age. This has important implications for counseling 
unaffected mutation carriers. Increased penetrance with increasing age indirectly supports 
the hypothesis of „late-onset‟ disease. Indirect evidence from cross-sectional data, does 
not prove this theory however and longitudinal cohort studies are required to accurately 
define the risk of developing disease in an individual. Our data suggests that in practice   84 
this is an uncommon occurrence – „late-onset‟ disease was only demonstrated in 1 adult 
despite moderately rigorous serial evaluations (see also Results: Longitudinal Follow-
Up). 
 
Disease penetrance appears to be unrelated to mutation type. This is perhaps surprising as 
different mutation types might be expected to confer different mechanisms disease 
expression. It suggests a common final pathway leading to the development of 
hypertrophy independent of mutation type. It is particularly interesting that penetrance is 
incomplete even in individuals with complex genetic status and two disease causing 
mutations. Reports of severe neonatal HCM have been seen in families with complex 
genetic status with two mutations (insertion + splice site mutation in one neonate and 
deletion + nonsense mutation in another), and severe hypertrophy has been reported in a 
47 year old male homozygous for a MYBPC3 missense mutation [Garcia-Castro 2005]. 
In contrast we demonstrated two individuals without clinical evidence of disease despite 
carrying two disease causing mutations, supporting the role of powerful disease 
modifying factors. 
These modifying factors (genetic or environmental) apparently influence disease 
development independent of specific mutation, mutation type or age. This study is the 
first to report a gender difference in disease penetrance with a higher proportion of male 
mutation carriers affected than female. This observation is consistent with males being 
overrepresented in HCM cohorts [Maron 2003b][Olivotto 2005]. There are several 
possible explanations for this observation, including sex-chromosome factors or sex-
hormone differences which affect disease expression, environmental triggers or modifiers   85 
such as athletic training may be more common in males than females. Gender specific 
differences in hypertrophy development have been observed in animal models [Witt 
2008] and gender differences have been reported in ECG derived hypertrophy regression 
in response to antihypertensive therapy [Okin 2008]. Identifying gender specific 
differences in HCM is important for at least two reasons: firstly it may guide 
investigators in a direction for further study which may improve our understanding of 
how, when and why disease develops and possible determinants of disease expression in 
this disease, and secondly it may lead to more directed and individual counselling for 
unaffected relatives in terms of the likelihood of developing disease in the future.  
Recent interest is focusing on single nucleotide polymorphisms (SNPs) and the role they 
might play in modifying disease penetrance and disease expression [Marian 2002]. 
Angiotensin converting enzyme (ACE) polymorphisms have been demonstrated to affect 
magnitude of LVH in individuals with HCM related to MYBPC3 mutations [Perkins 
2005], but the effect on disease penetrance has not been studied. A similar study in 26 
individuals from a single family with an insertion mutation in MYBPC3 suggested that 
the development of LVH occurred in those family members with „pro-LVH‟ genotypes 
(in ACE, angiotensinogen, angiotensin II receptor type 1, chymase A and aldosterone 
synthase genes) and not in those without [Ortlepp 2002]. This was true for LV mass, 
septal thickness and the prevalence of an abnormal ECG. While providing useful insight 
into the potential role of modifier mutations, by controlling for the main disease causing 
mutation, the clinical significance of identifying such modifiers is uncertain. The age at 
diagnosis in this cohort of affected individuals with MYBPC3 mutations is very wide and 
normally distributed. From these data there are no apparent clinically important   86 
differences between individuals diagnosed early or late – they appear to have a similar 
pattern and magnitude of hypertrophy, and the types of mutation identified appeared to be 
similar. As age at diagnosis is normally distributed, the concept of late-onset disease is 
difficult to define and in this cohort has little clinical relevance.  
It must be remembered that age at diagnosis is not equivalent to the age at which 
hypertrophy develops which requires serial evaluation. Without control groups using 
individuals with other sarcomeric protein gene mutations, this study is unable to directly 
compare how these data are applicable to the overall HCM population.   87 
 
CLINICAL DISEASE EXPRESSION IN AFFECTED 
INDIVIDUALS WITH MYBPC3 MUTATIONS   88 
Introduction 
 
Detailed clinical data is lacking in cohorts of families with MYBPC3 mutations. Charron 
et al. found no significant differences in symptoms, ECG abnormalities, or pattern or 
degree of hypertrophy between two families (33 mutation carriers) sharing an identical 
splice acceptor site mutation (SAS Int20) and families with MYH7 mutations [Charron 
1998b]. A larger study (76 MYBPC3 mutation carriers, including the 33 SAS Int20 
carriers) by the same group compared symptoms, ECG and Echo parameters with 
families with MYH7 mutations. MYBPC3 mutation carriers were slightly older (41 v 35, 
p=0.02) and there were fewer deaths reported in this group (10 v 18, p=0.004). Mean 
septal thickness was 15 +/- 4mm, 30% had SAM and LVOT obstruction greater than 
30mmHg was present in 14% [Charron 1998a]. Erdmann et al reported a variable clinical 
course in 25 MYBPC3 mutation carriers but suggested that disease onset was earlier and 
invasive procedures (including ICD and septal ablation) were more common in families 
with protein truncations compared to those with missense or inframe deletions/insertions 
[Erdmann 2001]. In a large US study from the Mayo Clinic, index cases (i.e. no family 
screening was performed) with MYBPC3 mutations did not differ from patients with 
thick filament-HCM, thin filament-HCM, or mutation negative HCM with respect to age 
at diagnosis, severity of hypertrophy or incidence of major complications [Van Driest 
JACC 2004]. They did find more severe disease in patients with complex genetic status 
however. As discussed previously, data from the Mayo clinic is skewed towards 
individuals with obstructive HCM as it is a centre of expertise in surgical myomectomy, 
and such patients are over-represented in their cohort. 
   89 
Data is somewhat conflicting therefore and requires clarification. In this section detailed 
clinical assessment of 98 affected MYBPC3 mutation carriers is reported. 
 
Methods 
 
Index cases and affected relatives were evaluated as described in the Methods section. 
Demographic data, symptomatology, ECG, Echo, Holter monitoring and exercise data 
were recorded and analysed for 98 affected mutation carriers. Data is presented as 
number of individuals, with percentages in parentheses. Mean +/- SD is reported where 
relevant. In group comparisons, categorical data are compared using Chi-square test and 
continuous variables compared using independent sample Student‟s t-test. A p-value of 
<0.05 was considered statistically significant. 
 
Results 
 
Index Cases 
 
34 of 59 individuals were male (57.6%) – Table 10. Mean age at diagnosis was 40.1 +/- 
15.9 years, range 5-76 (Figure 13). Reason for diagnosis were as follows: Symptoms 32 
patients (54.2%), incidental finding 16 (27.1%), family screening 10 (16.9%) and in 1 
individual (1.7%) the diagnosis was made at autopsy following sudden cardiac death. 54 
of 59 index cases (91.5%) were of White European ethnic origin, 2 (3.4%) were Black 
and 3 (5.1%) were Asian. Ethnic mix in the cohort was broadly similar to our overall 
HCM cohort (including other sarcomeric protein mutations and non-genotyped   90 
individuals) – 91% White European, 2% Black and 6% Asian. Ethnic mix was also 
broadly similar to the ethnic composition of the general population derived from the last 
national census in 2001 – 92.1% White European, 2% Black, 4.0% Asian – [Census 
2001] 
Table 10  Clinical data for 59 index cases with mutations in MYBPC3 
  Total 
 
SD  Range 
 
Demographics       
Total individuals (n (%))  59(100)     
Male (n (%))  35(59.3)     
Age at diagnosis (years)  40.0  15.9  5-76 
White Ethnicity (n (%))  54(91.5)     
Symptomatic (n (%))  42(71.2)     
       
Initial ECG       
Sinus Rhythm (n (%))  55(93.2)     
LA enlargement (n (%))  36(61)     
PR interval (ms)  167  26  108-224 
QRSd (ms)  97  17  80-160 
Mean RE score  6.2  3.4  0-12 
       
       
First Echo       
LA dimension (mm)  42  7.2  24-60 
LVEDD (mm)  43  6.7  25-60 
LVESD (mm)  25  6.2  15-48 
FS (%)  44  8.5  20-63 
IVSd (mm)  19  5.6  8-37 
PWd (mm)  10  2.4  6-18 
MWT (mm)  20  5.8  9-37 
ASH (n (%))  51(86.4)     
Severe LVH ≥ 30mm (n (%))  2(3.4)     
Mid-systolic obliteration (n (%))  2(3.4)     
RVH (n (%))  3(5.1)     
LVOTG > 30mmHg (n (%))  18(30.5)     
Metabolic exercise test       
Peak VO2 ml/Kg/min  26.2  11.2  9.5-57.9 
% Predicted VO2 (%)  75  22  37-128 
Holter       
NSVT (n (%))  13(22)     
         91 
Figure 13    Age at Diagnosis in 59 Index Cases 
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55 of 59 index cases were in sinus rhythm at diagnosis (93.2%) with 2 (3.4%) in atrial 
fibrillation, 1 in an AV synchronous paced rhythm, and 1 unknown (presented with 
sudden cardiac death). Non-sustained ventricular tachycardia (NSVT – defined as 3 or 
more ventricular premature complexes at a rate > 120 bpm) on 24 hour Holter monitoring 
was present in 13 (22.0%) individuals. 36 (61.0%) had left atrial enlargement on ECG, 29 
(49.2%) fulfilled Sokolow Lyon criteria for LVH, 2 (3.4%) had bundle branch block and 
41 (62.5%) had a Romhilt Estes score ≥4. 
Most individuals had asymmetrical septal hypertrophy (86.4%) but other patterns of 
hypertrophy were observed including concentric (5.1%), eccentric (5.1%), apical (1.7%) 
and 1 (1.7%) undetermined (presented with sudden cardiac death). Mean septal thickness 
was 19 +/- 5.6mm, posterior wall 10 +/- 2.4mm and maximal wall thickness 20 +/- 
5.8mm (Figure 14).   92 
Figure 14    Pattern of Hypertrophy in 59 Index Cases 
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* Patient presented with sudden death, so pattern of hypertrophy not identified ante-mortem 
 
One female (28 years old at diagnosis) had progressive wall thinning and predominant 
restrictive physiology requiring cardiac transplantation age 43. Left ventricular outflow 
tract obstruction (peak gradient ≥ 30mmHg) was seen in 18 (30.5%) individuals, with 
mid-cavity obstruction in 2 individuals (3.4%) and biventricular ventricular hypertrophy 
in 3 (5.1%). There were no differences in age at diagnosis or maximal wall thickness 
between different mutation types (Figures 15&16 and Table 11).   93 
Figure 15    Age at Diagnosis in 59 Index Cases According to Mutation Type 
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Figure 16    Maximal Wall Thickness in 59 Index Cases According to Mutation Type 
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There were no statistically significant differences between different types of mutation in 
terms of age at diagnosis (p=0.970), % in sinus rhythm (p=0.521), LV cavity size 
(p=0.387) or maximal wall thickness (p=0.781). 
 
Table 11  Clinical and Demographic Data for 59 Index Cases with HCM According to 
Mutation Type 
  Nonsense  Ins/Del  Missense  Intronic  Complex 
Status 
Total  P – value 
 
Number of Individuals  5  10  26  10  8  61  - 
Male (n(%))  4 (80)  8 (80)  16 (61.5)  6 (60)  2 (25)  36 (59.0)  0.097 
Age at diagnosis (yrs)  40.0  38.5  41.4  37.1  40.4  40.0  0.970 
White Ethnicity (n(%))  4 (80)  9 (90)   25 (96.2)  9 (90)  6 (75)  55 (90.2)  0.431 
Symptomatic (n(%))  4 (80)  8 (80)  13 (50)  9 (90)  7 (87.5)  42 (70)  0.064 
               
Initial ECG               
Sinus Rhythm (n(%))  4 (80)  10 (100)  25 (96.2)  9 (90)  8 (100)  56 (91.8)  0.521 
First Echo               
LA dimension (mm)  43.8  45.5  41.1  42.1  41.0  42.1  0.703 
LVEDD (mm)  42.4  42.3  45.2  40.6  41.7  43.3  0.387 
LVESD (mm)  24.5  23.2  26.3  23.3  25.6  25.0  0.749 
FS (%)  45.3  46.0  43.8  44.5  38.3  43.5  0.615 
IVSd (mm)  18.0  22.4  17.5  20.1  18.1  18.8  0.294 
PWd (mm)  10.9  11.1  10.2  10.6  10.1  10.5  0.804 
MWT (mm)  18.6  22.0  19.2  21.1  19.0  20.0  0.781 
               
 
All Affected Mutation Carriers 
 
In addition to the 59 index cases, family screening identified a further 111 mutation 
carriers of whom a further 39 fulfilled diagnostic criteria for HCM. Therefore, of 170 
mutation carriers (index cases and relatives) a total of 98 individuals fulfilled diagnostic 
criteria for HCM. Clinical data is shown in Table 12.  
   95 
Table 12  Clinical data for 98 affected mutation carriers 
  Total  SD  Range 
 
Demographics       
Total individuals (n(%))  98(100)     
Male (n(%))  58(59.2)     
Age at diagnosis (years)  42.1  16.1  5-81 
White Ethnicity (n(%))  92(93.9)     
Symptomatic (n(%))  53(54.1)     
       
Initial ECG       
Sinus Rhythm  (n(%))  94(95.3)     
PR interval (ms)  169  32  108-333 
QRSd (ms)  96  17  72-160 
Mean RE score  5.4  3.6  0-12 
       
First Echo       
LA dimension (mm)  41.4  7.3  22-60 
LVEDD (mm)  43.7  6.7  25-60 
LVESD (mm)  26.0  6.5  10-48 
FS (%)  42.5  9.0  20-67 
IVSd (mm)  17.9  5.3  6-37 
PWd (mm)  10.3  2.5  5-18 
MWT (mm)  18.7  5.4  6-37 
       
 
Mean age at diagnosis was 42.1 +/- 16.1 years (range 5-81) (Figure 17). Mean septal 
thickness was 17.9 +/- 5.3mm, posterior wall thickness 10.3 +/- 2.5mm and maximal wall 
thickness was 18.7 +/- 5.4mm. 84 (85.7%) had ASH with 7(7.1%) concentric, 3(3.1%) 
eccentric and 3(3.1%) apical patterns of hypertrophy. In one individual the pattern of 
hypertrophy was unknown as he had presented with sudden cardiac death and the 
diagnosis of HCM was made at autopsy. 
Maximal wall thickness did not appear to be related to age (Figure 18). Note that there 
was only one individual diagnosed between the ages 0-9 who had a maximal wall 
thickness of 24mm. 
   96 
Figure 17    Age at Diagnosis in 98 Affected Mutation Carriers 
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Figure 18  Mean Maximal Wall Thickness in 98 Affected Mutation Carriers According to Age 
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In terms of risk factors for sudden cardiac death: 10 (10.2%) had previous history of 
unexplained syncope, 1 (1%) had maximal wall thickness > 30mm, 29 (29.6%) had a 
family history of sudden premature death in a relative < 40 years, 22 (22.4%) had NSVT 
on Holter monitoring and 12 (12.2%) had an abnormal blood pressure response on 
exercise. Sixty of 98 affected mutation carriers had a complete data set for risk 
stratification for sudden cardiac death (symptom and family history, Echo, 48 hour Holter 
and metabolic exercise test). The majority of these 60 individuals were index cases. The 
remaining 38 were largely affected relatives diagnosed during family screening who were 
due to be followed up at their local cardiac centre rather than at the Heart Hospital. Of the 
60 with complete data, 12 (20%) had 2 or more risk factors for sudden death, with the 
remaining 48 (80%) being considered at low or intermediate risk (≤1 risk factor) (Figure 
19). This is similar to the overall HCM cohort at the Heart Hospital with 83% being at 
low or intermediate risk (1 risk factor) and 17% having 2 or more risk factors (data 
derived from HCM database representing an unselected HCM cohort). 
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Figure 19  Risk factor profile at first assessment in 60 affected mutation carriers with complete 
data 
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Index Cases Compared to Relatives 
Compared to index cases, relatives diagnosed via family screening had less severe septal 
hypertrophy (16 v 19mm, p=0.002), less severe maximal wall thickness (17 v 21mm, 
p<0.001), greater LV cavity size (LVEDD 46 v 42mm, p=0.012, LVESD 28 v 24, 
p=0.006) and mean Romhilt Estes score was less (4.4 v 6.3, p=0.018) (Table 13). 
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Table 13  Comparison between index cases and relatives diagnosed during family screening 
  Index cases  Relatives  P-value 
 
Demographics       
Total individuals (n)  59  39  - 
Male (n(%))  35(59.3)  23(59.0)  0.973 
Age at diagnosis (years)  39.8 +/- 15.7  44.6 +/- 16.3  0.141 
White Ethnicity (n(%))  54(91.5)  1(2.6)  0.412 
Symptomatic (n(%))  40(67.8)  11(28.3)  0.002 
       
Initial ECG       
PR interval (ms)  170 +/- 26  168 +/- 38  0.746 
QRSd (ms)  98 +/- 18  93 +/- 15  0.151 
Mean RE score  6.3 +/- 3.3  4.4 +/- 3.8  0.018 
       
First Echo       
LA dimension (mm)  42.3 +/- 7.8  40.2 +/- 6.5  0.167 
LVEDD (mm)  42.2 +/- 6.8  45.7 +/- 6.0  0.012 
LVESD (mm)  24.3 +/- 6.5  28.1 +/- 5.8  0.006 
FS (%)  44.0 +/- 9.1  40.2 +/- 8.6  0.105 
IVSd (mm)  19.5 +/- 5.5  16.0 +/- 4.5  0.002 
PWd (mm)  10.5 +/- 2.4  10.1 +/- 2.6  0.490 
MWT (mm)  20.5 +/- 5.6  16.6 +/- 4.5  0.000 
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Discussion 
 
In this section a number of clinical data on 59 index cases and 39 affected relatives have 
been presented. The main findings relating to MYBPC3 mutations in this cohort can be 
summarized as follows: 
1.  Disease may be diagnosed at any stage in life (5-81 years) and affected 
individuals are more commonly male (57.6%) 
2.  There is a wide spectrum of disease in terms of pattern and magnitude of 
hypertrophy and symptomatic status 
3.  Affected relatives were less symptomatic with milder hypertrophy than index 
cases 
4.  Mutation type was not related to age at diagnosis or magnitude of hypertrophy 
 
Previous studies have attempted to describe sarcomeric protein gene mutations in terms 
of particular phenotype, by comparing summary statistics between different cohorts 
[Charron 1998b]. While this may highlight statistically significant differences in 
particular clinical parameters, it does not necessarily reflect the spectrum and variation of 
disease that may be encountered for any given genotype.  
 
The summary data from this study are broadly similar to those data published previously 
[Moolman 2000][Richard 2003][Van Driest 2004][Song 2005] however detailed clinical 
data in affected individuals with MYBPC3 mutations are lacking, and are obscured by the 
inclusion of data from unaffected mutation carriers [Charron 1998a][Charron 1998b], or 
such data are lacking [Niimura 1998][Doi 1999][Erdmann 2001][Andersen 2004]. Study   101 
cohorts were similar in terms of age at diagnosis and maximal wall thickness (Table 14) 
suggesting that the individuals in this cohort are similar to the broad population of 
families with MYBPC3 mutations. 
Table 14  Summary data for affected MYBPC3 mutation carriers in this and previously 
published studies 
  This study  Van Driest  Richard  Song  Moolman 
Number of Individuals  98  63  48  16  10 
% Male  58  65  48  -  40 
Mean age at diagnosis 
(years)  42  38  40  48  - 
Mean maximal wall 
thickness (mm)  19  23  -  20  21 
           
 
Data from this study demonstrate a broad spectrum of disease. MYBPC3 mutation may 
cause severe hypertrophy at age 5 (H851) or sub-clinical disease diagnosed at family 
screening age 81 (H151). Some families have multiple cases of sudden cardiac death 
(H936) whereas other families appear to have a more benign clinical course (H544). Even 
within families sharing the same mutation, the spectrum of disease appears wide (see 
Disease Expression in Families Sharing Identical Mutations). For many of these 
important parameters, ranges are broad and standard deviations are wide. 
This study lacks a directly comparable control group, although it is possible to compare 
to the overall HCM population at The Heart Hospital, and previously published data 
would suggest that MYBPC3 related disease is not dissimilar to disease associated with 
other sarcomeric protein gene mutations. Van Driest et al compared clinical data from 63 
index cases with data from cohorts of thick filament (MYH7, MYL2 and MYL3) and thin 
filament (TNNT2, TNNI3, TPM1 and ACTC) mutations [Van Driest 2004]. No 
differences in age at diagnosis, severity of hypertrophy, incidence of myectomy or family 
history of HCM or sudden death were apparent between the groups.    102 
Whether the broad spectrum of disease seen in our cohort is applicable to the wider HCM 
population is unproven.  
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DISEASE EXPRESSION IN FAMILIES SHARING 
IDENTICAL MUTATIONS   104 
Introduction 
 
Following the recognition that mutations in sarcomeric protein genes are found in 
approximately 50% of cases of HCM [Richard 2003], interest has focussed on whether 
gene-specific, or mutation-specific phenotypes exist that may guide family counselling, 
clinical management and further our understanding of the pathogenesis of HCM. 
 
Early reports, necessarily based upon highly selected families suitable for linkage 
analysis, suggested that a specific phenotype could be attributed to a specific sarcomeric 
protein gene [Anan 1994][Watkins 1995b][Poetter 1996][Moolman 1997][Niimura 
1998][Charron 1998a][Mogensen 1999][Satoh 1999 [Hoffman 2001][Niimura 
2002][Mogensen 2004][Carniel 2005][Kubo 2007]. 
Moreover, early studies suggested that mutation specific differences exist, and reports of 
“malignant” and “benign” mutations in MYH7 and also in TNNT2 suggested a role for 
genetic analysis in risk stratification [Watkins 1992][Anan 1994][Consevage 
1994][Marian 1995a][Coviello 1997][Moolman 1997][Hwang 1998][Marian 1998][Ho 
2000][Roberts 2001][Van Driest 2002][Ackerman 2002]. 
 
While this is an attractive concept, potentially allowing the clinician or geneticist to 
provide a family with mutation specific advice, most mutations are private and novel and 
large numbers of individuals from separate families are required to confirm or refute the 
original claims regarding disease expression for that specific mutation. Van Driest et al. 
performed a meta-analysis examining gene specific differences pooling data from several 
large studies published between 1998 and 2004 and found no statistical differences in   105 
terms of age at diagnosis, or severity of hypertrophy between populations with different 
sarcomeric protein gene mutations [Van Driest 2005]. While certain specific MYH7 
mutations are felt to have an adverse prognosis [Marian 1995a] it is less clear whether 
risk in MYBPC3 families is mutation specific. 
 
Systematic genetic screening programmes in unselected HCM cohorts allows comparison 
of families sharing the same mutation. While this study is limited to MYBPC3 mutations 
and therefore precludes gene specific comparisons, it does allow mutation specific 
comparisons to be made between families sharing the same MYBPC3 mutation. 
 
Methods 
Six mutations were identified in at least 2 unrelated families (Table 15.). Clinical data 
was compared between families sharing each identical mutation and is reported below. 
 
Table 15  Spectrum of mutations shared by more than one family 
Mutation  Families  Total Number of 
Gene Carriers 
Previously Reported 
Mutation? 
Arg495Gly  H481, H600  3  No 
Arg502Gln  H62, H151  15  Yes 
Arg502Trp  H82, H448, H525, H579, H596, H819, H846, H851, H908  25  Yes 
Gln969X  H652, H936  9  Yes 
Glu258Lys  H432, H621, H919  8  Yes 
IVS13-23G>A  H692, H896, H920  6  No 
       
 
 
Results 
Arg495Gly Mutation 
Two families shared the novel Arg495Gly mutation. In one family (H481) the proband 
presented age 67 with dilated phase HCM and incessant atrial arrhythmias. He died age   106 
82 secondary to heart failure. No other family members were known to be affected, and 
his two children refused clinical and genetic screening. In another family (H600) with the 
same Arg495Gly mutation, the proband was diagnosed incidentally age 17 and found to 
have asymmetric septal hypertrophy (MWT 22mm) and paroxysmal AF treated with 
amiodarone. An ICD was implanted as primary prophylaxis for unexplained syncope and 
an abnormal blood pressure response to upright exercise. Her mother was diagnosed 
during family screening age 37 and found to have asymmetric septal hypertrophy (MWT 
16mm). No other family members were affected and four relatives were negative for the 
family mutation. 
Arg502Gln Mutation 
Two families shared the Arg502Gln mutation. The proband of family H151 was 
diagnosed incidentally age 14. Investigations showed severe septal hypertrophy (MWT 
37mm) but the patient remains asymptomatic during follow up. His sister is a gene carrier 
with an abnormal ECG but has shown no evidence of hypertrophy on Echo during 17 
years of follow up. Their father was diagnosed with HCM during family screening 
(asymmetric septal hypertrophy MWT 24mm) and is asymptomatic. Four other family 
members were found to be gene carriers. Two of these fulfilled diagnostic criteria for 
HCM (45 year old man with mild ASH and an 81 year old man with mild concentric 
LVH) and two did not fulfill diagnostic criteria (53 year old woman with abnormal ECG 
and normal Echo and 23 year old woman with normal ECG and Echo). There were no 
sudden deaths or strokes in this family. In contrast in family H62, the proband was 
diagnosed with HCM at post mortem having died suddenly age 16. Seven other adult 
family members were gene carriers. Of these 3 were clinically affected – 51 year old man   107 
with end-stage HCM and heart failure, 14 year old asymptomatic girl with apical 
hypertrophy and 54 year old man with hypertension and mild ASH which regressed 
during follow up. He died of a haemorrhagic stroke age 64. The other 4 had no evidence 
of disease expression during 18 years of follow up (now aged 57, 39, 37 and 34). 
R502W Mutation 
This mutation was identified in 9 apparently unrelated families (8 as the sole mutation 
and 1 in whom the MYH7 H602S mutation was also identified). The data described 
below is only for those individuals with a single R502W mutation.  
All 9 families were Caucasian and haplotype analysis identified a probable founder 
effect, the first to described in a British HCM population. 
Of 25 mutation carriers, 12 fulfilled diagnostic criteria for HCM and 13 were unaffected. 
The overall penetrance was 48%. In one family (H448) all three mutation carriers were 
clinically affected (100% penetrant), whereas in 3 other families with at least 2 adult 
mutation carriers the penetrance was incomplete (H851, H819 and H846). Of the 12 
affected individuals, 3 were diagnosed incidentally, 4 presented with symptoms and 5 
were diagnosed at family screening. Age at diagnosis was very different between the 
families with one male (H851.1) presenting age 5 with breathlessness, and one female 
(H579.6) presenting age 80 with an abnormal ECG. Age at diagnosis is shown in Figure 
20. Summary data for these families is shown in Table 16.    108 
Table 16  Summary data for affected patients with R502W mutation 
  Mean  Range  Standard deviation 
Age at diagnosis (years)  41.9  5-80  18.8 
% Male (%)  50     
Echo parameters       
LA diameter (mm)  37.3  24-45  1.8 
IVSd (mm)  15.1  10-24  1.1 
PWd (mm)  9.8  6-16  0.8 
MWT (mm)  16.9  13-24  1.1 
LVEDD (mm)  45.5  25-55  2.4 
LVESD (mm)  27.5  15-35  2.0 
FS (%)  39.6  26-63  3.1 
       
 
 
 
 
Figure 20  Age at diagnosis for individuals with the R502W mutation 
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Disease penetrance varied between families sharing the R502W mutation (Figure 21). In 
H448 for example all 3 mutation carriers were affected whereas in H819 only 1 of 7 
mutation carriers was affected.  
 
Figure 21  Disease Penetrance in Families Sharing the R502W Mutation 
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Pattern and extent of hypertrophy varied significantly: One individual had severe 
asymmetric septal hypertrophy with a maximal wall thickness of 38mm, while other 
patients had either mild ASH or other patterns of hypertrophy (see Figure 22.)   110 
Figure 22  Pattern of Hypertrophy in 25 mutation carriers with the R502W mutation. 
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Prognosis appeared to vary between families with multiple premature sudden cardiac 
deaths occurring in two families (H82 and H846), and a more benign prognosis in other 
families. In H82, H82.3 died suddenly age 36 in 1992. The post mortem noted pulmonary 
oedema, marked left ventricular hypertrophy with a heart weight of 400g and evidence of 
viral myocarditis on initial histology. Review of his histology 14 years later during this 
study however revealed widespread interstitial fibrosis and marked myocyte disarray. 
DNA was extracted from tissue blocks preserved at the time of death and attempts at 
DNA analysis would suggest that he was not a carrier for the R502W mutation. Due to 
the lack of a whole heart specimen and poor DNA quality the diagnosis and mutation 
status in this individual is not clear and limits the conclusions that can be drawn. His 
sister also died suddenly at the age of 12 in 1965. No post mortem was performed. The 
surviving sibling H82.2 is overweight with hypertension and was clinically unaffected. 
He was also wild type for the R502W mutation. This raises the possibility that another 
mutation was present in this family that may have contributed to the instances of sudden   111 
cardiac death, possibly paternally inherited. Interestingly the father of these three children 
was clinically unaffected.  
Another family (H846) also had 3 instances of premature death although details were 
lacking. One male child died suddenly age 4 and was reported to have Tetralogy of Fallot 
(unconfirmed). Another female died suddenly age 15 at a bus stop and was reported to 
have „aortic coarctation and myocardial degeneration‟ – also unconfirmed. One other 
female died less than 12 months old of unknown causes. Interestingly, 2 second degree 
relatives in this family are clinically affected but do not carry the R502W mutation. In the 
case of H846.3 all other sarcomeric protein genes have been screened and no other 
mutations identified. This also raises the possibility that another (unidentified) mutation 
is present in this family and may be relevant to the reported cases of premature sudden 
cardiac death (albeit not confirmed to be related to HCM).  
 
The risk factors for sudden cardiac death in those affected individuals were assessed. 
Complete risk stratification was complete in only 8 out of 12 individuals with no 
metabolic exercise test data available for 4 individuals, and no Holter data available for 2 
individuals. 
Risk factor profiles are shown in Figure 23. 
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Figure 23  Spectrum of Risk Factors in Individuals with the R502W Mutation 
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During long term follow up of affected mutation carriers (mean 6.6 years +/- 1.3), 1 
woman developed heart failure, there were no sudden cardiac deaths or cardiac arrests, no 
individuals underwent LV myomectomy or alcohol septal ablation and 2 prophylactic 
ICDs were implanted. No appropriate ICD therapies were recorded during follow-up. 
The R502W mutation has been reported previously in several studies [Richard 2003][Van 
Driest 2004][Ingles 2005] but unfortunately no mutation specific data has been reported. 
It is therefore not possible to compare the observed phenotype in this study to the 
published literature.   113 
 
Gln969X Mutation 
Two Caucasian families shared this nonsense mutation causing a premature stop codon. 
Once again the two families appear to have a very different clinical course. H652 is a 
large family, the index case of which (H652.1) presented in 1985 with effort intolerance 
and breathlessness. He was subsequently found to have ASH with provokable mid-cavity 
obstruction but no LVOTO, and severe diastolic dysfunction with restrictive filling 
pattern using transmitral pulsed wave Doppler. He remains limited by exertional 
symptoms despite medical therapy. Attempts at cardiac resynchronization therapy were 
unsuccessful due to phrenic nerve stimulation. Three siblings and his mother were found 
to be wild type for the Gln969X mutation. There are no other family members know to be 
affected, and no family history of sudden cardiac death. It is possible that the mutation 
has arisen de novo in the index case. 
In contrast, H936 manifests a particularly severe phenotype with multiple sudden cardiac 
deaths. The index case in the family (H936.1) presented age 29 with exertional 
breathlessness and was found to have ASH without outflow tract obstruction. His mother 
is affected with a mild phenotype but two of her siblings died suddenly at a young age 
and a further sibling survived a cardiac arrest and underwent ICD implantation. Three 
other siblings are clinically affected with a variable phenotype (H939.9 – asymptomatic 
with non-obstructive ASH and H936.7 – very limited with left ventricular outflow tract 
obstruction, heart failure, previous stroke and atrial fibrillation). Two other relatives are 
unaffected mutation carriers. A 3 year old girl is asymptomatic with a normal ECG and   114 
Echo for her age and a 43 year old woman is also asymptomatic with a normal ECG and 
Echo. The overall penetrance of disease in adults in this family is 86%.  
Glu258Lys Mutation 
Three Caucasian families shared this missense mutation.  
In H621 the index case presented age 26 in 1991 with a murmur found at a routine 
medical examination. He was found to have ASH without LVOTO and is in permanent 
atrial fibrillation. His mother was an obligate carrier for the mutation (as both her 
children are carriers, and her husband is wild type for the family mutation) and died 
suddenly on the waiting list for a heart-lung transplant. She had ASH with restrictive 
physiology and developed severe pulmonary hypertension and right sided heart failure.  
H919 is a family with fully penetrant disease expression in all four mutation carriers. The 
index case (H919.1) presented age 21 with chest pain. She was found to have ASH 
without obstruction and has no risk factors for sudden cardiac death. Her brother and 
mother are both gene carriers with mild disease expression but are both asymptomatic. 
H919.6 died age 79 with post-mortem showing evidence of left ventricular hypertrophy 
and DNA analysis showing her to be a mutation carrier. She was asymptomatic prior to 
death and not known to have HCM ante-mortem. 
In H432 the index case (H432.1) presented for family screening following the sudden 
cardiac death of her son age 19. He didn‟t have a post-mortem examination but had been 
diagnosed with HCM 7 weeks prior to his death in 1996. At family screening the only 
other mutation carrier identified was his mother (H432.1) who was asymptomatic but had 
mild ASH on transthoracic echo. She remains asymptomatic 10 years later.    115 
IVS13-23G>A Mutation 
Three families shared this intronic mutation which creates a de novo acceptor splice site, 
extending the transcript by 17 nucleotides, creating a frameshift and ultimately a 
premature stop codon in exon 15 [Frank-Hansen 2008]. They were of different ethnic 
origins (1 White British family, 1 Greek Cypriot family and 1 Asian family).  
H920.1 was a highly trained athlete who presented with syncope age 15. He was found to 
have ASH with a maximal wall thickness 17mm and no outflow tract obstruction. Other 
family members declined screening.  
H692.1 presented age 43 with chest pain and was found to have an eccentric pattern of 
hypertrophy involving the lateral wall and apex predominantly. No other mutation 
carriers have been identified in the family. 
H896.1 presented in 2001 with longstanding history of breathlessness and fatigue. He 
was found to have ASH, with a maximal wall thickness of 18mm and severe outflow tract 
obstruction with a peak resting gradient of 140mmHg. He subsequently underwent 
surgical myomectomy in 2001 and remains asymptomatic during follow up. Three other 
mutation carriers were identified in this family. His brother (age 25) and father (age 60) 
are both asymptomatic and unaffected. His paternal uncle however is also a mutation 
carrier and is clinically affected with ASH but is asymptomatic.    116 
Discussion 
 
Although the number of individuals sharing a particular mutation in this study is small, it 
is evident that disease expression can be very different between individuals with an 
identical mutation. This is true for age at diagnosis (compare family H851 vs H579), 
family history of sudden cardiac death (H82 and H846 vs H448 and H579), and pattern 
and extent of hypertrophy (H851 vs H579). It is of particular interest that the pattern of 
hypertrophy can be so variable between individuals with the same (R502W) mutation 
with all types of ventricular hypertrophy seen in this sub-cohort. This suggests that 
factors independent of the mutation specific molecular abnormality in these families 
influence how, when and where hypertrophy develops.  
A major limitation of studying disease expression in families is the cross sectional design 
– HCM is a chronic disease and therefore longitudinal cohort studies are required to 
identify age-dependent trends. Longitudinal follow up of these individuals is beyond the 
scope of this thesis but may provide important insights into disease expression in the 
future.  
The major clinical implication of these data is that counseling relatives in families in 
which the mutation is known and has been previously reported in the literature should 
remain a general discussion of the principles of HCM inheritance and not try to include 
mutation specific information based upon limited published data.  
 
As individual institutions will always be limited by the infrequency of a particular 
mutation in their own cohort it is likely that international databases are required to report 
clinical data for a given mutation, increasing the statistical power, to allow important   117 
trends (if they exist) to emerge. Even if such mutation specific trends do exist, it is 
evident from this study that at least some of the variance in disease expression is related 
to factors independent of the family mutation. It is likely that a combination of genetic 
factors (complex genetic status, disease modifier genes, polymorphisms and possibly 
gender (see Disease Penetrance, Age and Gender in Families with MYBPC3 Mutations) 
and environmental factors such as physical training and hypertension may play a role in 
determining the eventual phenotype in any individual. 
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EARLY DIAGNOSTIC MARKERS OF DISEASE 
EXPRESSION   119 
Introduction 
 
In a disease state with age-related and incomplete penetrance it is theoretically desirable 
to be able to predict which individuals are likely to develop disease in the future as this 
may allow early intervention to reduce the risk of adverse events. 
Data from a transgenic rabbit model of HCM has suggested that reduced myocardial 
Doppler velocities may identify mutation carriers irrespective of ventricular hypertrophy 
[Nagueh 2000]. Further studies in humans have supported the role of tissue Doppler 
imaging in identifying unaffected mutation carriers [Nagueh 2001] and even predicting 
which individuals go on to develop HCM during longitudinal follow up [Nagueh 2003]. 
Data from other investigators have been inconsistent however [Ho 2002][Cardim 2002].  
In order to study this issue further, a number of clinically derived parameters were 
assessed in a large genotyped population in order to assess whether it is possible to 
accurately identify unaffected mutation carriers from control subjects from clinical data 
alone. 
Methods 
 
As part of an ongoing study we have identified a cohort of 59 index cases fulfilling 
diagnostic criteria for HCM and a disease causing mutation in the MYBPC3 gene. First 
and second degree relatives were invited to participate in this study and undergo clinical 
and genetic evaluation. Evaluation included history, clinical examination, 12-lead 
electrocardiogram (ECG) and transthoracic echocardiography (Echo). All at risk relatives 
were considered eligible and were only excluded if their Echo data was of insufficient 
quality to allow detailed analysis as described below.   120 
ECGs were analysed (blinded to genotype) for the presence of pathological and non-
pathological Q waves, Romhilt Estes score, Sokolow Lyon Criteria, T wave inversion (> 
1mm in two consecutive leads), bundle branch block (QRS duration > 0.12s), axis 
deviation and atrial enlargement. Definitions used in ECG analysis are shown in Table 
17. 
Table 17  Definitions used in ECG analysis 
Parameter  Definition  Score 
Romhilt Estes Score  Voltage Criteria (any of): 
R or S in limb lead > 20mm 
S in V1 or V2 > 30mm                                   3 points 
R in V5 or V6 > 30mm 
ST-T Abnormalities 
With Digoxin                                                  1 point 
Without Digoxin                                             3 points 
Left Atrial Enlargement in V1                                       3 points 
Left axis deviation                                                          2 points 
QRS duration > 90ms                                                     1 point 
Intrinsicoid deflection in V5 or V6 > 50ms                   1 point 
Scored out of 14. Scores 
> 4 considered to 
represent LVH 
Sokolow Lyon Criteria  S in V1 + R in V5 or V6 > 35 mm  Yes or No 
Cornell Criteria  S in V3 + R in aVL > 24 mm (men) 
S in V3 + R in aVL > 20 mm (women) 
Yes or No 
Abnormal Q Wave  Duration > 40ms and greater than 1/3 ensuing R wave height  Yes or No 
Left atrial enlargement  biphasic P wave in V1 with terminal deflection > 1mm and >0.04s 
duration 
Yes or No 
T wave abnormality  Flat or inverted T wave  Yes or No 
     
Konno 2005b 
 
Transthoracic echo data was analysed off-line (EchoPAC, GE Healthcare, Little 
Chalfont, UK) according to published criteria [Gardin 2002]. Septal and posterior wall 
thicknesses were measured at end-diastole by M-mode in the parasternal long-axis view 
as well as LV end-diastolic and end-systolic dimensions. LA diameter was measured in 
the parasternal long and short axis, and apical views. Mitral valve inflow pulsed wave 
Doppler was recorded to measure E and A wave velocity, E/A ratio, E wave deceleration, 
A wave duration, time velocity integral and isovolumic relaxation time. Pulmonary vein 
Doppler was recorded to measure S, D and A wave velocities, D wave deceleration time 
and time velocity integrals. Pulsed tissue Doppler recordings were made at the mitral 
annulus at the septum and lateral wall, and anterior and inferior walls when possible. All   121 
measurements were made by one observer (SK) who was blinded to the genetic status of 
each individual.  
Longitudinal strain and strain rate were calculated from colour Doppler myocardial 
imaging data of the apical 4chamber view. Due to Doppler angle dependence, analysis 
was performed only at the basal and mid segments of the septal and lateral wall using 
high frame rate acquisitions (>140fps). Sample volume size was 10x2mm with 
continuous wall tracking and maximum measurements were averaged over 3 consecutive 
cardiac cycles. Technically adequate recordings obtained from 10 unaffected mutation 
carriers were matched for age and gender with 10 normal controls. 
 
Statistics 
Relatives were categorised into 3 groups on the basis of their genetic and clinical status: 
Mutation negative control subjects (Group 1), unaffected mutation carriers who did not 
fulfil diagnostic criteria for HCM (maximal LV wall thickness <13mm) (Group 2) and 
mutation carriers fulfilling diagnostic criteria for HCM (LV wall thickness >13mm) 
(Group 3). Means and standard deviations were calculated for continuous variables and 
Student‟s t-test (comparing groups 1 and 2) and ANOVA (comparing all three groups) 
were used to compare differences between groups. For categorical variables the Chi-
square test was used. A p-value < 0.05 was considered statistically significant. 
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Results 
 
A total of 96 individuals were included in the study including 56 mutation carriers with 
24 mutations, from 27 families. In two families more than one disease causing mutation 
was identified (complex genetic status). The spectrum of mutations is shown in Table 18.  
Table 18  Spectrum of MYBPC3 Mutations in Early Diagnosis Study 
Mutation  Mutation Type  Number of Mutation Carriers 
g_18567delCT 
R502Q 
R502W 
698delC 
g14271delC 
g16190_16196delGCGTCTA 
Q969X 
E258K 
G341R 
IVS1-2A>G 
IVS13-2A>G 
IVS14-13G>A 
IVS18+7G>A + D880D 
IVS20-2A>G 
K1055X 
IVS9-36G>A 
V1125M + IVS9-1G>C 
P873Q 
Q425X 
R943X 
T750M 
T957S 
Insertion/deletion 
Missense 
Missense 
Insertion/deletion 
Insertion/deletion 
Insertion/deletion 
Nonsense 
Missense 
Missense 
Intronic 
Intronic 
Intronic 
Complex  
Intronic 
Nonsense 
Intronic 
Complex 
Missense 
Nonsense 
Nonsense 
Missense 
Missense 
1 
7 
12 
2 
5 
1 
2 
2 
1 
2 
1 
1 
1 
3 
3 
1 
1 
2 
1 
2 
3 
2 
     
 
There were 40 mutation negative control subjects (Group 1), 39 unaffected mutation 
carriers (Group 2) and 17 mutation carriers fulfilling diagnostic criteria for HCM (Group 
3). The yield in terms of identifying individuals who fulfil diagnostic criteria for HCM 
from the screening programme was 17.7%.  Baseline clinical and echo data is shown in 
Table 18. Although there were slightly more females than males in Group 2 this was not 
statistically significant (χ
2 =1.0, 1 df, p=0.311). Affected individuals were older and more 
symptomatic. Mutation types were similar between the three groups (data not shown).   123 
There were no significant differences in terms of LV cavity dimensions (LVEDD 48.5 v 
47.7, p=NS), septal thickness (8.5 v 9.1, p=NS) or maximal wall thickness (8.8 v 9.5, 
p=NS) between mutation negative individuals and unaffected mutation carriers. 
 
Table 19  Clinical and demographic data of 96 individuals screened for HCM 
  Group 1 
Mutation Negative 
Group 2 
Unaffected 
Mutation Carriers 
Group 3 
HCM 
p-value 
Group1 vs Group2 
Number of Individuals (n)  40  39  17  - 
% Male  55.0  43.6  58.8  NS 
Mean Age (Years)  38.5 +/- 16.7  37.4 +/- 16.8  47.3 +/- 15.3  NS 
Transthoracic Echo Measurements 
LA size (mm) 
LVEDD (mm) 
LVESD (mm) 
IVSd (mm) 
PWd (mm) 
Maximal wall thickness (mm) 
FS (%) 
 
34.3 +/- 4.3 
48.5 +/- 5.0 
31.4 +/- 4.4 
8.5 +/- 1.4 
8.1 +/- 1.3 
8.8 +/- 1.5 
48.1 +/- 4.5 
 
35.0 +/- 4.8 
47.7 +/- 5.2 
30.9 +/- 4.0 
9.1 +/- 1.6 
8.6 +/- 1.5 
9.5 +/- 1.6 
47.4 +/- 4.8 
 
37.7 +/- 7.0 
44.0 +/- 4.5 
29.0 +/- 5.6 
13.9 +/- 4.6 
8.7 +/- 1.4 
15.3 +/- 4.3 
43.4 +/- 4.5 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
         
* Students t-test comparing Groups 1 and 2 only. 
 
ECG Measurements 
Categorical and continuous ECG variables were compared between mutation negative 
(Group 1) and unaffected mutation carriers (Group 2) (Tables 20&21). Six mutation 
negative individuals had an abnormal ECG (5 were hypertensive and 1 had a history of 
previous anterior myocardial infarction). The prevalence of LA enlargement (20.5% v 
2.5%, p=0.012) and non-pathological Q waves (64.1% v 27.5, p=0.001) were more 
common in Group 2 (non-pathological Q wave: defined as a negative deflection with a 
duration < 40ms and an amplitude < 1/3 the height of the ensuing R wave). Unaffected 
mutation carriers had higher mean Romhilt Estes scores (1.4 vs 0.8, p=0.042), but a RE 
score > 4 was no more common in Group 2 (7.8% v 5.0, p=0.623). Mean S wave 
amplitudes were greater in Group 2 for leads V2 (16.6 v 12.4mV, p=0.023) and V3 
(12.7mm v 9.3, p=0.023). The proportion fulfilling Cornell criteria for LVH were more   124 
common in Group 2 but this did not reach statistical significance (17.9% v 5.0, p=0.070). 
Eight (21%) unaffected mutation carriers had T wave inversion on the ECG (7 lateral or 
high lateral leads and 1 anteriorly) compared to 3 (8%) mutation negative controls 
(p=0.095).  
Overall, 15 of 39 (38.5%) unaffected mutation carriers had an abnormal ECG (defined as 
fulfilling either Cornell criteria, Sokolow Lyon criteria or a Romhilt Estes score ≥4). In 
comparison 6 of 40 (15%) mutation negative controls had an abnormal ECG (Chi square 
5.57, 1 df, p=0.18) 
 
Table 20  ECG measurements 
  Group 1 
Mutation Negative 
Group 2 
Unaffected Mutation 
Carriers 
Group 3 
HCM 
p-value 
Group 1 v Group 2 
Heart rate (bpm)  69 +/- 14  69 +/- 12  66.5 +/- 14.2  0.907 
PR Interval (ms)  157 +/- 19  155 +/- 21  166 +/- 49  0.570 
QRS duration (ms)  86 +/- 10  86 +/- 10  89 +/- 12  0.926 
Mean Romhilt Estes 
Score  0.8 +/- 1.2  1.4 +/- 1.6  3.1 +/- 3.9  0.042 
Total QRS Voltage (mV)  136 +/- 45  149 +/- 48  146 +/- 48  0.208 
S wave V1  9.6 +/- 5.2  10.9 +/- 4.7  10.5 +/- 4.7  0.229 
S wave V2  12.4 +/- 8.2  16.6 +/- 7.9  12.7 +/- 6.6  0.023 
S wave V3  9.3 +/- 6.1  12.7 +/- 6.9  13.1 +/- 6.1  0.023 
R Wave V5  12.0 +/- 5.2  11.8 +/- 4.6  9.8 +/- 4.2  0.835 
R Wave V6  9.9 +/- 3.8  9.8 +/- 3.9  8.9 +/- 4.2  0.950 
R Wave aVL  3.6 +/- 3.2  3.9 +/- 2.7  6.1 +/- 5.8  0.606 
         
Data presented as mean +/- SD 
Table 21  Sensitivity and Specificity for Categorical ECG Parameters 
 
Group 1 
Mutation 
Negative 
Group 2 
Unaffected 
Mutation 
Carriers 
Sensitivity (%)  Specificity (%) 
P-value 
Chi-square 
LA Enlargement (n(%))  1(3)  8(21)  21  98  0.012 
Pathological Q Waves (n(%))  1(3)  0(0)  0  98  0.320 
Non-pathological Q Waves (n(%))  11(28)  25(64)  64  73  0.001   125 
Sokolow Lyon Criteria (n(%))  2(5)  1(3)  3  95  0.571 
Cornell Criteria (n(%))  2(5)  7(18)  18  95  0.070 
Romhilt Estes Score > 4 (n(%))  2(5)  3(8)  8  95  0.623 
Abnormal T Wave Inversion (n(%))  3(8)  8(21)  21  93  0.095 
           
 
Echo Measurements 
There were no differences in standard measurements of cavity size and wall thickness 
between groups 1 and 2 (Table 22). LA width measured in the apical 4 chamber view was 
greater in Group 2 however (37.2mm v 34.3, p=0.017) although other measurements of 
LA dimensions were no different. Indices of mitral valve pulsed wave Doppler were no 
different between the two groups. Pulmonary vein Doppler indices were also evaluated. 
AR wave duration was greater in Group 2 (115ms v 105, p=0.047) and D wave 
deceleration time was shorter (203ms v 232, p=0.038). All other indices were similar 
between the two groups. 
Table 22  2D and Doppler Echo Measurements 
  Group 1 
Mutation 
Negative 
Group 2 
Unaffected Mutation 
Carriers 
Group 3 
HCM 
p-value 
Group 1 v Group 2 
(t-test) 
LA dimension PLAX (mm)  34.3 +/- 4.3  35.7 +/- 4.9  38.4 +/- 6.0  0.184 
LA dimension SAX (mm)  34.5 +/- 5.0  35.3 +/- 5.2  39.7 +/- 7.8  0.474 
LA depth A4C (mm)  45.7 +/- 5.8  47.2 +/- 5.6  50.2 +/- 5.9  0.254 
LA width A4C (mm)  34.3 +/- 4.8  37.2 +/- 5.7  36.8 +/- 6.3  0.017 
E Velocity (cm/s)  0.8 +/- 0.2  0.8 +/- 0.1  0.8 +/- 0.2  0.524 
A Velocity (cm/s)  0.6 +/- 0.2  0.6 +/- 0.2  0.7 +/- 0.3  0.866 
EA ratio  1.5 +/- 0.7  1.5 +/- 0.5  1.2 +/- 0.5  0.824 
E Deceleration time (ms)  195 +/- 35  190 +/- 36  203 +/- 54  0.591 
A Duration (ms)  124 +/- 16  123 +/- 19  117 +/- 22  0.680 
Isovolumic relaxation time (ms)  94 +/- 19  90 +/- 17  105 +/- 27  0.264 
E Wave VTI (cm/s)  12.0 +/- 2.8  12.8 +/- 2.5  13.7 +/- 4.4  0.166 
A Wave VTI (cm/s)  5.4 +/- 2.0  5.1 +/- 2.0  6.3 +/- 2.8  0.510   126 
S wave velocity (cm/s)  59.0 +/- 9.3  55.1 +/- 7.7  54.8 +/- 14.6  0.057 
D wave velocity (cm/s)  53.0 +/- 
17.0 
53.4 +/- 12.3  44.5 +/- 10.0  0.869 
AR velocity (cm/s)  24.9 +/- 5.6  26.1 +/- 7.1  31.0 +/- 9.3  0.421 
AR duration (ms)  105 +/- 21  115 +/- 22  114 +/- 21  0.047 
D Wave deceleration time (ms)  232 +/- 58  203 +/- 56  239 +/- 71  0.038 
S wave VTI (cm/s)  16.5 +/- 3.1  16.1 +/- 4.0  15.4 +/- 2.6   0.642 
D wave VTI (cm/s)  12.4 +/- 3.7  12.1 +/- 3.5  11.2 +/- 3.2  0.764 
AR wave VTI (cm/s)  2.4 +/- 0.7  2.7 +/- 0.8  3.1 +/- 1.0  0.167 
         
 
Tissue Doppler velocities at the mitral valve annulus were also compared. Late-diastolic 
velocities at the lateral annulus were greater in Group 2 (Aa 8.9 cm/s v 7.5, p=0.005) but 
all other indices were similar between the two groups (Table 23). 
Table 23  Tissue Doppler Measurements 
  Group 1 
Mutation Negative 
Group 2 
Unaffected Mutation 
Carriers 
Group 3 
HCM 
P-value 
Group 1 v Group 2 
Sa Lateral  Annulus 
(cm/s)  9.8 +/- 2.6  10.1 +/- 2.4  9.4 +/- 2.5  0.598 
Ea Lateral Annulus 
(cm/s)  13.4 +/- 4.9  13.3 +/- 3.9  9.4 +/- 3.7  0.972 
Aa Lateral Annulus 
(cm/s)  7.5 +/- 1.9  8.9 +/- 2.3  9.1 +/- 3.5  0.005 
E/Ea Ratio Lateral  6.0 +/- 1.8  5.8 +/- 1.2  9.6 +/- 8.6  0.615 
IVRT Lateral Annulus 
(ms)  75.8 +/- 17.5  81.3 +/- 16.3  92.5 +/- 19.2  0.173 
Sa Septum (cm/s)*  8.1 +/- 1.4  7.9 +/- 1.6  7.0 +/- 1.9  0.716 
Ea Septum (cm/s)*  10.1 +/- 2.7  9.0 +/- 2.8  7.9 +/- 4.3  0.328 
Aa Septum (cm/s)*  8.1 +/- 21.1  7.3 +/- 1.3  7.9 +/- 1.1  0.251 
IVRT septum (ms)*  92.0 +/- 21.1  92.5 +/- 13.8  106 +/- 39.8  0.952 
         
* - Due to suboptimal image quality TDI data at the septum was measured in 18 individuals in Group 1, 9 Group 2 and 7 Group 3 
 
Having excluded those with an abnormal ECG (6 from Group 1 and 9 from Group 2, in 
order to assess the role of Echo in the context of a normal ECG) the observed differences 
persisted between the two groups in terms of 2D, Doppler and tissue Doppler indices: LA   127 
4-chamber width (p=0.018), D deceleration time (p=0.041), Lateral Aa velocity 
(p=0.021), AR duration was no longer different between the two groups however 
(p=0.257). 
 
Strain and Strain-rate Imaging 
A sub-group of individuals with adequate image quality were selected for strain and 
strain-rate imaging analysis off-line. Data from 10 unaffected mutation carriers and 10 
age and sex matched mutation negative control subjects were evaluated (Table 24). No 
significant differences were observed for any parameters between the two groups. 
Table 24  Strain and Strain-rate Imaging in sub-groups of Groups 1 and 2 
Parameter  Group 1 (n=10)  Group2 (n=10)  P – value 
Mean age  37.4 +/- 13.9  36.0 +/- 16.3  0.837 
% Male  50.0    50.0  - 
Strain       
Sa septum (%)  5.5 +/- 0.8  5.7 +/- 0.9  0.616 
Ea septum (%)  8.6 +/- 2.0  7.4 +/- 2.6  0.252 
Aa septum (%)  6.0 +/- 1.3  6.2 +/- 1.9  0.864 
Ea/Aa ratio septum (%)  1.6 +/- 0.7   1.4 +/- 0.9  0.603 
Sa lateral (%)  6.3 +/- 1.9  7.1 +/- 2.0  0.339 
Ea lateral (%)  10.5 +/- 4.2  9.8 +/- 3.3  0.722 
Aa lateral (%)  4.7 +/- 1.1  6.6 +/- 2.2  0.026 
Ea/Aa  lateral (%)  2.4 +/- 1.1  1.8 +/- 1.2  0.281 
Basal septum (%)  21.9 +/- 7.4  14.7 +/- 6.4  0.042 
Mid septum (%)  24.5 +/- 8.5   21.0 +/- 4.6  0.277 
Basal lateral (%)  20.6 +/- 7.1  20.6 +/- 7.7  0.992 
Mid lateral (%)  14.9 +/- 5.1  16.2 +/- 6.0  0.639 
Strain rate       
Basal septal (s
-1)  1.4 +/- 0.9  1.1 +/- 0.5  0.372 
Mid septal (s
-1)  1.7 +/- 0.8  1.4 +/- 0.5  0.229 
Basal lateral (s
-1)  1.4 +/- 0.4  1.6 +/- 0.6  0.511 
Mid lateral (s
-1)  1.1 +/- 0.3  1.2 +/- 0.5  0.675 
       
 
Lateral Aa velocity was greater in Group 2 (6.6 v 4.7, p=0.026) and basal septal strain 
was reduced (14.7 v 21.9, p=0.042).    128 
 
Discussion 
 
In this study the clinical value of a large number of ECG and Echo measurements in 
predicting genetic status in a large cohort of unaffected HCM family members has been 
assessed.  The main findings were as follows: 
  Several ECG abnormalities including LA enlargement and deep S waves in V1 
and V2 were more common in unaffected mutation carriers compare to controls 
  Tissue Doppler indices were clinically unhelpful in predicting genetic status and 
previous data suggesting useful role for reduced Ea and Sa velocities were not 
confirmed in this study 
 
Previous studies have examined the ability to predict genotype from clinically derived 
parameters. Hagege et al. examined ECG criteria and 2D and M-mode Echo parameters 
in 100 genotyped individuals (20 unaffected mutation carriers) [Hagege 1998]. 50% had 
an abnormal ECG. When compared to gene negative individuals, unaffected mutation 
carriers had greater maximal wall thickness (9.7 vs 8.9mm), greater LV mass indexed for 
body surface area (107 vs 97g/m
2) and larger left atrial volume (27 vs 23 mm
3). They 
concluded that disease expression is a continuous spectrum from normal cardiac structure 
to typical ventricular hypertrophy.  
Following early experimental data from transgenic rabbits, Nagueh et al examined the 
role of tissue Doppler imaging in 3 groups of highly selected, age and sex matched 
individuals: 1) control subjects 2) mutation carriers without LVH and 3) mutation carriers   129 
fulfilling diagnostic criteria for HCM [Nagueh 2001]. There were 13 unaffected mutation 
carriers with mutations in MYH7, TNNT2 and MYBPC3 genes and had no evidence of 
LVH on ECG or Echo. Systolic (Sa) and early diastolic (Ea) velocities were reduced 
compared to normal controls at both the septum and lateral mitral annulus, but to a lesser 
extent than in patients with HCM. E/Ea ratio (a marker of LV filling pressure) at both the 
septum and lateral mitral annulus were increased. Late diastolic velocities (Aa) were 
similar in both unaffected mutation carriers and controls. Not only were the statistical 
means different between groups but lateral Sa velocity of <13cm/s had a sensitivity of 
100% and specificity of 93% for differentiating between unaffected mutation carriers and 
controls. Similarly a lateral Ea velocity < 14 cm/s had a 100% sensitivity and 90% 
specificity. Septal Sa <12 cm/s and Ea < 13 cm/s both had 100% sensitivity and 90% 
specificity. The authors concluded that tissue Doppler derived data was able to reliably 
distinguish between unaffected mutation carriers and mutation negative controls and 
could thus prove useful in families with familial HCM where the mutation was unknown.  
 
In a second study the same group published follow-up data from 12 of the 13 unaffected 
mutation carriers over a two year period (age 17-51) [Nagueh 2003]. 6 of these 12 
individuals developed maximal LV wall thickness > 13mm, thus fulfilling diagnostic 
criteria for HCM. No significant changes between baseline and follow-up were noted in 
transmitral Doppler indices. Tissue Doppler parameters were also measured at baseline 
and at follow-up. Systolic (Sa) and early diastolic (Ea) velocities at both the septum and 
lateral mitral annulus were significantly reduced compared to controls at follow up. E/Ea 
ratio at the septum and lateral annulus remained higher at follow up compared to   130 
controls. The authors concluded that these data confirmed the potential role of tissue 
Doppler imaging to identify unaffected mutation carriers who may subsequently develop 
left ventricular hypertrophy. 
 
Ho et al. examined tissue Doppler parameters in 18 unaffected MYH7 mutation carriers 
from 5 families and controls [Ho 2002]. Most mutation carriers (Asp 906Gly) came from 
a single family however (13 of 18 individuals). Ages were similar and transmitral 
Doppler indices were no different between the two groups. There were no statistical 
differences in ECG parameters between the two groups. Unaffected mutation carriers had 
greater LV ejection fraction (71 vs 64%, p<0.0001). Early diastolic (Ea) velocities were 
reduced at the lateral, septal and inferior mitral annulus in unaffected mutation carriers, 
while systolic (Sa) and late diastolic (Aa) velocities were no different between the two 
groups. The authors remarked that there was considerable overlap of values between the 
two groups and cut-off values were neither sensitive nor specific for predicting genotype. 
Cardim et al. assessed tissue Doppler indices in 5 unaffected mutation carriers 
(Arg502Gln mutation in MYBPC3 gene) [Cardim 2002]. Compared with 10 normal 
controls subjects, mutation carriers had lower LV systolic velocities (Sa) and lower early 
diastolic (Ea) velocities, although there was no clinically useful cut-off value which 
accurately identified mutation carriers. 
 
The results from our study are somewhat inconsistent with those published previously. 
We identified several ECG abnormalities which were were more prevalent in unaffected 
mutation carriers compared to mutation negative controls. LA enlargement is a common   131 
abnormality in affected individuals and therefore LA enlargement on an ECG may 
represent evidence of early disease development. However while the specificity of LA 
enlargement on ECG was specific (98%) it was not sensitive in identifying unaffected 
mutation carriers. Unaffected mutation carriers also had higher mean Romhilt Estes 
scores (1.4 +/- 1.6 v 0.8 +/- 1.2), deeper S waves in V2 (16.6 +/- 7.9 v 12.4 +/-9.2mm) 
and deeper S waves in V3 (12.7 +/- 6.9 v 9.3 +/- 6.1mm) compared to mutation negative 
controls. Combined, these data suggest that ECG abnormalities occur early in disease 
development - and before hypertrophy develops. No ECG abnormality was sensitive 
however in identifying unaffected mutation carriers. Therefore while it is interesting to 
observe ECG abnormalities predating the development of hypertrophy (as detected by 
cardiac imaging), the ECG is unhelpful clinically in reliably predicting genotype, and 
does not allow the accurate identification of unaffected mutation carriers in this cohort. 
While Nagueh et al. [Nagueh2001] and Ho et al. [Ho 2002] reported reduced Sa and Ea 
velocities at the mitral annulus these results were not confirmed in this study. In our 
larger study, a cut-off of lateral Ea velocity < 14 had 40% sensitivity and 50% specificity 
in identifying mutation carriers. Lateral Sa velocity < 13 had sensitivity 50%, specificity 
50%. A septal Sa < 12 was 100% but 0% specific and septal Ea <13 was 70% sensitive 
and 30% specific, although adequate TDI data from the septum was obtained in a small 
number of individuals. There was considerable overlap between the two groups however 
and no indices reliably or consistently identified mutation carriers. In our study, the Aa 
velocity at the lateral annulus was increased in unaffected mutation carriers compared to 
control subjects. This result was not observed in other published studies and contradicts   132 
the expected finding of reduced Aa velocities in subjects with clinically evident 
hypertrophy.  This may therefore represent a Type 2 statistical error. 
 
There are a number of explanations for different findings between our study and other 
published data. Although systolic TDI velocities are independent of age, diastolic 
velocities (Ea and Aa) are highly age dependent [Henein  2002]. The mean ages in 
affected mutation carriers and controls in the study by Ho et al. were 24 and 26 years 
respectively (NS) and 35 and 36 years (NS) in the study by Nagueh. In our study the 
mean age of unaffected mutation carriers (Group 2) was 37 and 39 (NS) for mutation 
negative controls. It is possible, but unlikely therefore, that differences in age explain the 
different findings. In our study 44% of mutation carriers were male compared to 55% 
mutation negative controls, compared to 40% and 60% in the study by Ho et al. and 23% 
and 23% in the study by Nagueh et al. As the findings by Nagueh et al were largely in 
women it is possible therefore that gender specific differences in disease penetrance 
account for the lack of positive result in our study. The TDI velocities, especially at the 
lateral annulus were lower in our control group than one might expect [Henein 2002]. 
Within this group however were individuals with other pathologies such as hypertension 
and ischaemic heart disease. We specifically chose to assess the role of early diagnostic 
markers in a practical, clinical setting however and therefore did not exclude such 
individuals.  
This study was limited to data from families with mutations in the MYBPC3 gene. This is 
the most common gene in which disease causing mutations occur [Van Driest 2004] and 
by limiting the study in this way gene specific differences should be avoided. Importantly   133 
this study included a large range of mutations, representative of the overall cohort of 
MYBPC3 related disease. It is possible however that our findings are not necessarily 
applicable to the wider HCM population.  
 
Not previously reported is the role of deformation imaging in predicting genotype in this 
context. We found no significant differences between unaffected mutation carriers and 
controls in this regard. Although there are technical and methodological difficulties 
associated with deformation imaging [Teske 2007], the overall quality of data was high in 
this study and the two groups were well matched for age and sex, the lack of a positive 
result is likely to be real. 
 
In the absence of a known mutation in a family with HCM there are several theoretical 
advantages in identifying individuals before hypertrophy develops. Firstly in families in 
which the mutation is unknown, it could allow more focussed screening by selecting 
those individuals likely to, or at risk of, developing hypertrophy in the future. This has 
the potential advantage of avoiding unnecessary clinical visits by mutation negative 
individuals, which is beneficial both in terms of their own peace of mind and also of 
resource allocation. Secondly it could provide an opportunity to intervene at an early 
stage of the disease. Although to date there are no interventions that modify disease 
expression in humans, prophylactic ICD implantation in at risk mutation carriers is 
theoretically advantageous. Although sudden cardiac death in unaffected mutation 
carriers has been reported [McKenna 1990][Maron 1990], its incidence is poorly defined 
and how to best assess risk in unaffected mutation carriers is not known.   134 
 
The strengths of this study lie in the large number of individuals examined (greater than 
the combined published data to date) and the blinded design. Subtle statistically 
significant differences were identified between unaffected mutation carriers and controls, 
but no clinically useful cut-off values were identified to allow accurate blinded 
identification of mutation carriers with no clinical evidence of disease expression. While 
careful, technical evaluation of tissue Doppler indices may elucidate subtle differences 
(as published by Nagueh et al. and Ho et al.) in mutation carriers this remains of 
academic interest at present. It is interesting for example to note that identifying 
abnormalities of contractile function before hypertrophy is evident, supports the 
hypothesis that ventricular hypertrophy in HCM is compensatory. At present however 
tissue Doppler derived data do not allow the accurate identification of unaffected 
mutation carriers and thus do not allow a more focussed family screening strategy 
In summary, previously identified abnormalities of systolic and diastolic myocardial 
function in unaffected mutation carriers were not consistently confirmed in this study. 
While small studies in highly selected groups of individuals have suggested a role for 
tissue Doppler imaging in accurately identifying mutation carriers from controls, the 
application of such parameters does not appear to be relevant to clinical practice in this 
larger, less selected group of individuals. Family screening programmes ought to 
therefore continue to evaluate all relatives at risk of inheriting disease causing mutations 
for the time being.   135 
 
LONGTERM FOLLOW-UP DATA   136 
Introduction 
 
There are relatively few data describing the natural history of HCM in relation to 
MYBPC3 mutations. Most series of genotyped patients have used a cross-sectional 
design and detailed longitudinal cohort studies are lacking. Such data are important when 
trying to manage patients and their families, and in trying to anticipate and prevent 
complications in the future. As has already been discussed, the issue of whether 
echocardiographically detectable hypertrophy develops commonly in adulthood is 
particularly important. Existing longitudinal data relating to HCM in individuals and 
families with MYBPC3 mutations are summarised below. 
 
Maron et al described for the first time the development of ventricular hypertrophy in 
adults [Maron 2001]. Of 12 adult unaffected mutation carriers at initial evaluation, 5 were 
followed up prospectively, 3 (1 male) of whom developed echocardiographic ventricular 
hypertrophy at ages 33, 35 and 42. One individual had incomplete systolic anterior 
motion at initial evaluation age 29 with partial RBBB on ECG however, and another 
individual had an abnormal ECG with Q waves and T wave inversion at baseline age 27. 
In only one individual did hypertrophy develop with a normal ECG and Echo at baseline 
(age 38).  
 
Nagueh et al described LVH developing in 6 of 12 adult mutation carriers unaffected at 
baseline assessment. 7 of these 12 shared the InsG791 mutation in MYBPC3 although it 
is not clear how many of these 7 developed HCM during 2 years of follow-up [Nagueh 
2003].    137 
 
 
Kubo et al described longitudinal follow-up in 15 families sharing an identical Japanese 
founder mutation (V592fs/8) in MYBPC3 [Kubo 2005]. 39 mutation carriers were 
identified of which 30 fulfilled diagnostic criteria at initial assessment. During a mean 
follow-up period of 9.2 +/- 5.5 years AF was detected in 33% (3.6%/year). LA size 
increased from 40 +/- 8.3 mm to 46 +/- 9.0mm (p-value not reported). At last follow-up 7 
individuals had developed “end-stage” HCM defined as LV systolic dysfunction, cavity 
dilatation and irreversible heart failure. 6 of these 7 patients were 60 years or older. There 
were 2 stroke deaths, 1 heart failure death and 1 ICD discharge during follow-up (overall 
combined risk 1.4% per year). 
 
This part of the study examines the natural history of clinical disease related to MYBPC3 
mutations for both affected and unaffected mutation carriers.   
 
Methods 
 
Clinical data was compared at baseline and at last follow-up assessment for all mutation 
carriers with at least two clinical evaluations at least 12 months apart. Paired sample t-
tests were used to compare means. Data are presented as mean +/- standard deviation, or 
as percentages. A p-value < 0.05 was considered statistically significant. 
   138 
Results 
 
All Mutation Carriers 
Longitudinal follow up data was available for 84 mutation carriers. Of these, 67 were 
clinically affected at baseline. Mean age at start of follow up was 37.1 +/-16.4 years 
(range 5-76). Mean duration of follow-up was 7.9 +/- 4.5 years (range 1-19).  
 
Overall survival was 94.0% - there were 5 deaths (3 sudden, 1 heart failure, 1 stroke). 
The 3 sudden deaths occurred in the following individuals: 
  A 32 year old female (H588.2 with the IVS14-13G>A mutation) was diagnosed 
age 28 and followed up for 4 years. She had a maximal wall thickness of 22mm 
and had evidence of NSVT on Holter monitoring and an episode of syncope 
which occurred during physical exercise. Before prophylactic ICD implantation 
could be arranged she died suddenly while dancing. 
  A 58 year old man (H697.1 with the K1055X mutation) was diagnosed with 
obstructive HCM age 51 following an incidental finding of a cardiac murmur. He 
was asymptomatic until he developed AF at which stage he developed heart 
failure. He was treated with amiodarone. He had a maximal wall thickness of 
26mm, a positive family history of premature sudden cardiac death, and a 
borderline blood pressure response on exercise. He died suddenly age 58. 
  A 31 year old man (H934.1 with the g14274delC mutation) presented age 30 with 
acute pulmonary oedema while swimming. Subsequent investigations 
demonstrated asymmetric septal hypertrophy (maximal wall thickness 24mm)   139 
with incomplete SAM and NSVT on exercise. He died suddenly shortly 
afterwards. 
One individual (H608.1 with the intronic splice site IVS1-2A>G mutation) had 
progressive wall thinning and predominantly restrictive physiology and underwent 
cardiac transplantation for intractable heart failure. One individual was lost to follow up. 
The overall annual mortality rate was therefore 0.75% and annual risk of sudden death 
0.45%. The proportion of patients who were symptomatic was no different at baseline 
compared to follow-up (65.7% and 64.7%). 4 individuals underwent alcohol septal 
ablation and 2 underwent surgical myomectomy for symptomatic outflow tract 
obstruction. 13 individuals underwent ICD implantation (11 prophylactic, 2 following 
aborted sudden death). No appropriate ICD therapies (either anti-tachycardia pacing or 
DC shock therapy) were detected in 3.0 +/- 1.7 years (range 1-6). There were 5 strokes (1 
fatal, annual risk of stroke 0.75%) Arrhythmias were common however with 28.8% of 
individuals having documented NSVT on Holter monitoring and 18.3% developing at 
least one episode of AF during follow-up.  
Table 25  Event rates in 84 mutation carriers 
 
  Number (%) 
Symptom-free survival  35 (43.2) 
Alive  79 (94.0) 
Complications   
Cardiac transplantation  1 (1.2) 
Heart Failure Death  1 (1.2) 
Sudden death  3 (3.7) 
Heart Failure  9 (11.0) 
Atrial fibrillation  15 (18.3) 
NSVT or VT  23 (28.8) 
Survived Cardiac Arrest  1 (1.3) 
Stroke  5 (6.1) 
Infective Endocarditis  1 (1.2) 
Interventions   
Pacemaker  7 (8.4) 
Cardiac resynchronisation  1 (1.2) 
ICD  13 (15.7) 
Surgical myomectomy  2 (2.4) 
Alcohol septal ablation  4 (4.8) 
   
   140 
Affected Mutation Carriers 
Echocardiographic data for affected individuals at baseline and at follow-up was 
compared (Table 26 and Figures 24-31). Longitudinal follow up was associated with a 
reduction in septal thickness (16.5 at baseline v 15.2mm, p=0.033), increased LV end-
systolic diameter (25.5 v 28.6mm, p=0.000), reduced fractional shortening (41.6 v 37.0%, 
p=0.000) and increase in LA diameter (39.8 v 42.3 v mm, p=0.001). 13.4 % developed 
clinical symptoms of heart failure during follow up and dilated-phase HCM (defined as 
LVEDD > 55mm and FS < 25%) occurred in 2 individuals (3.0%). 
Table 26  Echocardiographic parameters at baseline and at last follow up in 67 affected 
mutation carriers 
  Baseline  Follow-up  P-value * 
Age (years)  37.1 +/- 16.4  47.0 +/- 16.9  0.000 
IVSd (mm)  16.5 +/- 6.6  15.2 +/- 6.4  0.033 
PWd (mm)  9.8 +/- 2.7  9.2 +/- 2.6  0.122 
MWT (mm)  17.6 +/- 6.7  16.8 +/- 6.2  0.166 
LVEDD (mm)  43.5 +/- 7.2  44.7 +/- 6.9  0.086 
LVESD (mm)  25.5 +/- 7.1  28.6 +/- 6.8  0.000 
FS (%)  41.6 +/- 9.1  37.0 +/- 8.2  0.000 
LA (mm)  39.8 +/- 8.2  42.3 +/- 8.6  0.001 
       
*Using paired-samples T-test. 
These data are shown graphically in Figures 24-31. Boxes represent the arithmetic mean 
with bars representing 95% confidence intervals. 
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Figure 24  Aortic Diameter at Baseline and Last Follow up  
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Figure 25  LA Diameter at Baseline and Last Follow up 
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Figure 26  LVEDD at Baseline and Last Follow up 
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Figure 27  LVESD at Baseline and Last Follow up 
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Figure 28  Septal Thickness at Baseline and Last Follow up 
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Figure 29  Posterior Wall Thickness at Baseline and Last Follow up 
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Figure 30  Maximal Wall Thickness at Baseline and Last Follow up 
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Figure 31  Fractional Shortening at Baseline and Last Follow up 
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Unaffected Mutation Carriers 
17 individuals who were clinically unaffected at baseline were followed up for a mean 
9.4 +/- 7.1 years (range 1-18). Mean age at baseline was 25.0 +/- 14.3 years (range 10-53) 
and 33.1+/- 14.8  years (range 11-66) at second evaluation. Of these 17 individuals 3 
(17.6%) developed clinical evidence of disease expression during follow up (Table 27). 2 
of the 3 developed evidence of disease expression at ages 13 and 14. The third individual 
(H610.8) (5.9% of those followed up) was first evaluated at age 39 and found to have a 
normal ECG and Echo. He came from a large family with a deletion mutation (698delC) 
with multiple affected family members. He was subsequently diagnosed with HCM 
during a routine health check age 53 on the basis of T wave inversion in the anterior chest 
leads and asymmetric septal hypertrophy on transthoracic echocardiography (maximal 
wall thickness 15mm). He had not been evaluated in the interim period so it is not known 
at what age the hypertrophy developed. There was no history of hypertension or athletic 
training and he remains asymptomatic. 
 
Table 27  Clinical Data for 3 Individuals developing LVH during the course of follow up. 
Individual  Mutation  Gender  Age 1 
(years) 
Age 2 
(years) 
MWT 1 
(mm) 
MWT 2 
(mm) 
ECG 1  ECG 2 
H610.13  Cys698del 
 
F  13  21  6  14 (eccentric)  Nonpathological 
Inferolateral Q 
waves 
Partial RBBB, 
pathological 
inferolateral Q 
waves 
H62.2  Arg502Gln  F  14  27  8  18 (apical)  NA  TWI V1-V4 
H610.8  Cys698del 
 
M  39  53  11  15 (ASH)  NA  TWI V2-V6 
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Figure 32  Maximal wall thickness in unaffected mutation carriers at initial evaluation 
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Summary Echo data is shown in Table 28. There were no statistically significant 
differences in Echo derived parameters at baseline and at last follow-up assessment in 15 
unaffected mutation carriers, despite three individuals developing hypertrophy during 
follow up. Changes in maximal wall thickness with time are shown in Figure 32. 
Table 28  Echo parameters in unaffected mutation carriers at initial evaluation 
  1
st Assessment  Last Assessment  P value 
Age (years)  25.5 +/- 15.2  33.5 +/- 15.5  0.001 
LA size (mm)  31.8 +/- 5.1  34.0 +/- 5.0  0.174 
LVEDD (mm)  49.5 +/- 5.8  47.3 +/- 5.9  0.272 
LVESD (mm)  32.7 +/- 3.7  31.8 +/- 4.4  0.253 
FS (%)  32.1 +/- 3.7  31.9 +/- 2.9  0.887 
IVSd (mm)  7.8 +/- 1.3  7.3 +/- 1.6  0.214 
PWd (mm)  7.7 +/- 1.6  7.5 +/- 1.6  0.723 
MWT (mm)  8.6 +/- 1.6  9.7 +/- 3.6  0.262 
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Discussion 
 
The main findings of this part of the study were as follows: 
1.  Annual mortality amongst mutation carriers was 0.75% per year 
2.  Annual sudden death rates were 0.45% per year 
3.  Left atrial diameter increases with age 
4.  LV end-systolic diameter increases and fractional shortening decreases with age 
5.  There is septal thinning but no decrease in maximal wall thickness with age 
6.  Hypertrophy can develop in adulthood but appears to be an uncommon event 
 
Previous studies have calculated annual complication rates amongst non-genotyped 
cohorts of patients with HCM (i.e. affected patients only).  
  The incidence of stroke is approximately 0.8% [Maron 2002a] – in our 
study the incidence of stroke amongst affected mutation carriers was 
0.94%.  
  The incidence of sudden death is approximately 1.02% [Elliott 2006b] – in 
our study the incidence of sudden death was 0.57%.  
  The published incidence of endocarditis is approximately 0.38 [Spirito 
1999] – in our study the incidence was 0.19 
The observed complication rates in our cohort are therefore similar to published rates for 
non-genotyped cohorts therefore, which is contrary to previous suggestions that 
MYBPC3 mutations are associated with a relatively good prognosis [Niimura 
1998][Charron 1998a][Charron 1998b][Richard 2003]. The event rates in this study are   148 
low however and the actual complication rates may be significantly different if the 
numbers studied were greater. 
 
Our study identified one patient who developed echocardiographic LVH during follow 
up. While this phenomenon has been described before [Maron 2001][Nagueh 2003], it 
appears to be an uncommon event and may not justify the current recommendations for 
periodic lifelong screening of unaffected adult relatives [Maron 2003a]. Large 
longitudinal follow-up studies are required in unaffected mutation carriers to better 
understand the frequency of hypertrophy development in adulthood. This study has now 
identified a cohort of unaffected mutation carriers who will continue to be followed up 
long-term and hopefully provide an insight into this important aspect of HCM 
epidemiology.   149 
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Conclusions 
 
Over the last 50 years since Donald Teare‟s early description [Teare 1958] our 
understanding of hypertrophic cardiomyopathy has increased significantly. Modern 
techniques of DNA analysis and advanced cardiac imaging have enhanced our 
knowledge of this fascinating condition and the great complexities of this condition have 
become apparent. While elements of clinical management are fluid, with imaging and 
therapeutic techniques coming in and out of fashion, certain „established facts‟ regarding 
HCM have been established. One such „fact‟ is the role of sarcomeric proteins in disease 
pathogenesis, and mutations in the gene encoding cardiac myosin binding protein-C are 
of central importance. Studying genotyped cohorts therefore provides the opportunity to 
gain further insights into the condition. 
 
In this thesis the largest cohort of HCM index cases with MYBPC3 mutations, and their 
families, have been described. Several important themes have emerged: 
 
  Complex genetic status is common which has major implications for mutation 
detection strategies and counselling families. 
  The spectrum of clinical disease is broad and even with individuals sharing a 
specific mutation, implying that disease modifying factors influence disease 
development and severity to a powerful degree. 
  Disease penetrance is incomplete and may be related to gender suggesting an area 
for further study   151 
  Clinical disease may present at any stage in life indicating that HCM should be 
part of the differential diagnosis in a patient presenting with cardiac symptoms at 
any age, and should be considered in anyone with affected family members. 
  Although age-related penetrance is suggested by cross-sectional data, disease 
developing de novo is rare during adulthood. Do family screening strategies need 
to accommodate this apparently rare event? In asymptomatic individuals, serial 
clinical assessment may be associated with a low yield in detecting new cases of 
HCM 
  Although the overall prognosis for this cohort is good, individual risk is highly 
variable and clinical management decisions need to reflect this 
  Clinically useful markers of early disease expression and genotype prediction is 
not possible with currently available indices  
 
This study has a number of strengths. This study describes the largest cohort of index 
cases to date with MYBPC3 mutations. The total number of mutation carriers (including 
family members) is the second largest to date with only one study [Niimura 1998] 
including more genotyped individuals. These data therefore add considerably to the body 
of knowledge available. Detailed clinical characterisation of such a cohort has never been 
previously performed and the longitudinal data presented are novel. Additionally, the 
evaluation of markers of early disease expression is in the largest genotyped cohort to 
date.  
Establishing accurate genotype-phenotype correlations requires large numbers of 
patients, multiple different mutations, and need to be repeated in different patient   152 
populations. The initial descriptions of MYBPC3 mutations, in highly selected families, 
may have over-emphasised the frequency and clinical relevance of „late-onset‟ disease 
therefore, leading to premature assumptions of late-onset and benign disease. A major 
strength of this study therefore is that families were unselected and included a broad 
spectrum of mutations that is representative of MYBPC3 related disease as a whole. 
  
There are a number of limitations to this study however.  
 
Tertiary referral centres inevitably introduce an element of referral bias (such as the over-
representation of obstructive HCM at the Mayo Clinic). While this is true, the reputation 
of the Inherited Cardiovascular Disease Unit at The Heart Hospital, London, and 
previously at St George‟s Hospital, London, is not based upon a particular clinical 
problem such as surgical myomectomy, and the reasons for referral are broad and include 
a wide range of patients. Indeed the international reputation of the Inherited 
Cardiovascular Disease Unit indicates that an inclusive demographic cohort is described. 
Therefore both patients with complex clinical problems, referred for expert opinion, and 
patients referred routinely for assessment from the local catchment area are represented. 
 
This study lacks a comparative group, or a cohort of patients with mutations in another 
sarcomeric protein gene. It would clearly be advantageous to directly compare clinical 
indices between cohorts of patients with other sarcomeric protein mutations, but detailed 
clinical evaluation of such cohorts is beyond the scope of this study. This study is   153 
therefore limited to comparisons with previously published data regarding MYBPC3 
mutations and unselected cohorts of HCM index cases. 
A further limitation was that due to limited clinical resources we were unable to fully 
clinically evaluate unaffected family members with ambulatory ECG monitoring and 
metabolic exercise testing. While there is not a strong clinical indiciation to evaluate 
unaffected family members in this way, having a cohort of unaffected mutation carriers 
provides a unique opportunity to fully investigate the phenotype of HCM. Unfortunately 
it was not possible to perform ambulatory ECG monitoring and metabolic exercise testing 
in all patients due to limited clinical availability. 
 
What might the future hold? 
 
The role of single gene genotype-phenotype studies is probably coming to an end 
[Ackermann 2005]. To data studies have been limited by small family size, a low 
frequency of each specific mutation and inability to assess and control other disease 
modifying factors [Marian 2001]. More sophisticated models of disease that include a 
monogenic mutation with other genetic and environmental variables are required. The 
Human Genome Project allows a new era of genetic evaluation to begin with single 
nucleotide polymorphisms (SNPs) and their effect on monogenic disorders to be 
investigated [Marian 2002]. Studying families sharing an identical mutation provides a 
good opportunity to study candidate variables [Marian 2002] and controlling mutation 
specific variation by studying founder mutations is an attractive direction for future 
studies. Large longitudinal cohort studies of genotyped families are required to determine   154 
the frequency of adult-onset disease and gain insights into the natural history of 
hypertrophic cardiomyopathy. Given the limitations of individual centres, establishing 
international databases and a collaborative approach is desirable [Arbustini 2002]. 
 
Although classifying, and establishing diagnostic criteria for HCM has proved 
problematic [McKenna 1997][Richardson 1996][Maron 2003a][Maron 2006][, redefining 
HCM in the genetic era will be required to include mutation carriers not fulfilling 
diagnostic criteria – whether these individuals are at risk of sudden complication remains 
unclear, but even if this is the case this risk is probably not great. 
 
The significant body of literature published to date has probably raised as many questions 
as it has answered, but with careful systematic clinical and genetic evaluation our 
knowledge can only be enhanced. It is hoped that the data presented in this thesis 
contributes, in a small part, to this body of knowledge. 
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The appendix contains the following: 
 
1.  Information sheet provided for relatives prior to obtaining informed consent. 
2.  Informed consent sheets used for aquiring blood samples for genetic analysis in 
relatives. 
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Hypertrophic Cardiomyopathy -  
 
An information sheet for relatives 
 
 
 
What is Hypertrophic Cardiomyopathy? 
People who are affected by hypertrophic cardiomyopathy (HCM) often have thickening 
of the heart muscle. Some do not have symptoms of disease while others may experience 
episodes of breathlessness, chest pain, and palpitations or have attacks of dizziness or 
fainting. 
 
HCM is hereditary (inherited), and is therefore likely to run in families. In recent years 
changes in certain genes have been found to cause HCM. These genes make proteins in 
the sarcomere. Sarcomeres are fibres of the muscle that make the heart contract to pump 
blood around the body. Someone who carries a change in one of these genes has a 50% 
risk of passing the disease onto each of their children. Fortunately, a substantial number 
of the individuals carrying the gene change are healthy and have no major symptoms 
from the disease. 
 
 
Why am I giving blood? 
A relative of yours has HCM and has previously seen Professor McKenna in London. 
Genetic investigations showed a change in one of the genes causing HCM. Based on the 
nature of the specific change found we assume that this change is the disease causing 
agent within your family. There is a chance that you also have this change and by giving 
a blood sample we can test for this change. This will help us decide whether you have 
HCM or not. 
 
 
What other tests do I need? 
We would also like you to have a simple heart trace (ECG) and a heart scan (Echo). 
These tests are to look for evidence of heart muscle thickening that is part of the disease. 
The Heart Hospital 
Cardiology Department 
16-18 Westmoreland StreetLondon 
W1G 8PH  
 
Telephone: 020 7573 8888  
Fax:  020 7573 8838 
Web-site: www.uclh.org   169 
 
 
What happens next? 
The results for the genetic test will take several months to arrive. When we have the 
results, we can compare your result with the result of the ECG and Echo scan. We will 
base any decision making upon your ECG and Echo scan, but will let you know your 
genetic result which may help us to understand the condition in your family better. 
 
If you have any questions, please do not hesitate to get in touch. 
 
 
 
Dr Steve Page 
Clinical Research Fellow to Professor WJ McKenna 
 
Department of Inherited Cardiovascular Disease 
47 Wimpole Street 
The Heart Hospital 
London  W1G 8PH 
 
Telephone:  0207 573 8888 Ext 4908 
E-mail:    steve.page@uclh.nhs.uk 
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